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Introduction
!
This is the third of three guidelines (parts I – III)
within the framework of the European Federation
of Societies for Ultrasound in Medicine and Biology
(EFSUMB) Guidelines on Interventional Ultrasound
(INVUS) describing ultrasound (US)-guided percu-
taneous diagnostic and therapeutic interventions
of the abdomen. Part III deals with the indications
and clinical impact of US-guided therapeutic inter-
ventions and gives evidence-based recommenda-
tions for the safe and efficient performance of these
techniques using the available evidence at the time
of manuscript preparation. It is complemented by
guidelines on general aspects of US-guided inter-
ventions (part I) [1] and US-guided diagnostic in-
terventions (part II) [2]. In addition, EFSUMB also
publishes guidelines on the use of diagnostic and
therapeutic endoscopic ultrasound interventions
[3, 4] and ultrasound-guided vascular interventions
[5].
Methods of guideline development are described
in the introduction to the EFSUMB Guidelines on
Interventional Ultrasound [6]. Levels of evidence
(LoE) and Grades of Recommendations (GoR)
have been assigned according to the Oxford Cen-
tre for Evidence-based Medicine criteria (March
2009 edition) [http://www.cebm.net/oxford-cen-
tre-evidence-based-medicine-levels-evidence-
march-2009].
Local ablative procedures of the liver
!
Introduction
Local ablative procedures play a key role in the
management of patients with malignancies, pri-
marily with hepatocellular carcinoma (HCC), but
also with metastases [7–10].
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Abstract
!
The third part of the European Federation of Socie-
ties for Ultrasound in Medicine and Biology (EF-
SUMB) Guidelines on Interventional Ultrasound
(INVUS) assesses the evidence for ultrasound-guid-
ed and assisted interventions in abdominal treat-
ment procedures. Recommendations for clinical
practice are presented covering indications, contra-
indications, and safe and effective performance of
the broad variety of these techniques. In particular,
drainage of abscesses and fluid collections, inter-
ventional tumor ablation techniques, intervention-
al treatment of symptomatic cysts and echinococ-
cosis, percutaneous transhepatic cholangiography
and drainage, percutaneous gastrostomy, urinary
bladder drainage, and nephrostomy are addressed
(long version).
Zusammenfassung
!
Der dritte Teil der Leitlinien der European Federa-
tion of Societies for Ultrasound in Medicine and
Biology (EFSUMB) zur interventionellen Sonogra-
fie (INVUS) bewertet die Evidenz für transkutane
sonografisch gestützte und assistierte therapeuti-
sche Interventionen im Abdomen. Auf der Grund-
lage publizierter Daten werden zu Indikationen,
Kontraindikationen sowie zur sicheren und effi-
zienten Durchführung Empfehlungen für die kli-
nische Praxis gegeben. Berücksichtigung finden
die sonografisch geführte Drainage von Abszes-
sen und Flüssigkeitsansammlungen, Tumorabla-
tionstechniken, transkutane Zystensklerosierung
symptomatischer Zysten und der Echinokokkose,
die perkutane transhepatische Cholangiografie
und Drainage, die perkutane Gastrostomie, die
Harnblasenpunktion und Drainage sowie die Ne-
phrostomie (Langversion).
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The short-term clinical outcome is improved by a multi-modality
approach discussed at multidisciplinary team meetings. The re-
ported success rates are multifactorial, and depend upon patient
selection and operator experience. The best outcome is delivered
when strict clinical criteria are followed and aided by multidisci-
plinary board discussions.
Most operators use a percutaneous approach, but laparoscopic
and laparotomic routes can also be used. Over the last 25 years,
different methods have been developed and used clinically. Per-
cutaneous ethanol injection (PEI) was the first widespread tech-
nique. Later on, thermal ablative procedures (radiofrequency ab-
lation (RFA), microwave and laser ablation) emerged rapidly.
Recently, novel US-guided ablative procedures have become
available (interstitial brachytherapy, irreversible electroporation
(IRE), and high intensity focused ultrasound (HIFU)) [11–15].
Treatment intention
Local ablative procedures can be classified according to the treat-
ment intention as curative or palliative [16, 17].
Curative intention
Tumor ablation is usually performed with curative intent. This
applies mainly to small HCCs (≤5 cm), as well as to colorectal liv-
er metastases [17–23]. The decision for local ablation over re-
section should take into account data such as the patient’s age,
co-morbidities, normal parenchymal reserve and tumor distri-
bution inside the liver, as well as the risks for metachronous tu-
mor growth, and all these should be weighed against the inva-
siveness of the procedure [16].
Recommendation 1
HCC ablation should be preferably performed with curative
intent (LoE 1a, GoR A). Strong consensus (100%).
Palliative strategy
The main indication for palliative treatment of liver tumors is
metastatic neuroendocrine tumor load. Other primary [24] and
secondary liver tumors may also be treated [16, 25–32].
Multi-modal treatment
With multiple liver metastases (commonly colorectal) not suit-
able for surgical resection because of their number or location
(e. g., proximity of vascular or biliary structures), a combined/
multimodal approach should be considered [33].
Ablation in conjunction with resection is increasingly used as a
parenchyma-sparing curative strategy that combines effective
ablative treatment of small tumors with resection of large tu-
mors, for which ablation is less effective [34–41]. Similar con-
cepts can be applied to hepatocellular carcinoma (HCC) in a cir-
rhotic liver, when extensive surgical sacrifice of the parenchyma
must be avoided.
Recommendation 2
Ablation in conjunctionwith resection may be considered as a
parenchyma-sparing curative strategy (LoE 2a, GoR B). Strong
consensus (100%).
Hepatocellular carcinoma (HCC)
The treatment options for HCC in a cirrhotic liver are transplan-
tation, surgical resection, local ablative therapies, transarterial
chemoembolization (TACE), radioembolization with Yttrium90
loaded beads (transarterial radioembolization (TARE), and, in
cases of advanced disease, systemic therapy with sorafenib
(Nexavar®). Image-guided percutaneous ablation therapies,
such as RFA [42–44], PEI [45–47] and microwave coagulation
[48], have been performed mainly with small HCCs, according
to the Milan criteria [49]. These are potentially curative, mini-
mally invasive, and repeatable in case of recurrence [50].
Local ablative treatment techniques for HCC
Radiofrequency ablation
The energy generated by RFA induces coagulation necrosis of the
tumor. Different systems have been introduced. Monopolar sys-
tems employ a neutral electrode (grounding pad) that is applied
to the body surface. The current flows between the ablation
probe in the tumor and the neutral electrode generates heat
concentrically around the probe. In bipolar RFA systems, both
electrodes are mounted close together on the same probe so
that all current flow occurs directly between the two electrodes;
a neutral electrode is not required. This arrangement has some
advantages; ablation can be performed with an active cardiac
pacemaker in place, provided that the ablation zone is not close
to the pacemaker. Bipolar systems also eliminate the danger of
skin burns from the neutral electrode used in monopolar sys-
tems. Multipolar systems in which three or more needles can
be used simultaneously in an alternating mode are also available
[16, 51, 52]. Complete removal of neoplastic tissue (R0) is com-
mon after surgical resection, while complete tumor necrosis fol-
lowing RFA is almost 90% for very small HCCs <2 cm and drops
to 50% to 70% for lesions between 3–5 cm and lower for larger
lesions [44, 53–57] due to the heat loss of perfusion-mediated
tissue cooling within the ablated region [44, 53, 55–59].
Size of tumors
As a single RFA needle usually coagulates a region ≤2–3 cm in di-
ameter, potentially non-spherical (depending on the RF system),
multiple sequential insertions may be required to achieve a safe-
ty margin in lesions ≥2–2.5 cm. In one series of 1000 RFA proce-
dures (2140 nodules) in 664 patients, complete ablation was ob-
tained using a mean number of electrode insertions of 1.5, 2.3,
4.2, and 11.7 for nodules of ≤2 cm, 2.1–3 cm, 3.1–5 cm, and
>5 cm respectively [59].
To overcome this limitation, multi-needle systems have been in-
troduced for simultaneous ablations and stereotactically guided
RFA that produce coagulation zones up to 7–10 cm [52, 60–
62]. There is no accepted maximum tumor size that can be abla-
ted in a single session but the size is generally in the 4–5 cm
range. Complete response (necrosis) following RFA is 80–90
percent for tumors < 3 cm [43, 55, 56, 63, 64]. Complete necrosis
rates are 50–70 percent for lesions between 3–5 cm and lower
for larger lesions [44, 53–57]. It is difficult to reliably complete-
ly treat tumors > 5–6 cm with current RFA devices. A small
study showed that the RFA zone was 3.4-fold larger in patients
who received a single dose of pegylated liposomal doxorubicin
(20mg IV) 24 hours prior to planned RFA, as compared to con-
trols (with RFA alone) [65]. This is a promising finding but the
evidence is currently inadequate.
The ablated zone should encompass the treated tumor and a cir-
cumferential margin of 5–10mm around the tumor [66]. Abla-
Dietrich CF et al. EFSUMB Guidelines on… Ultraschall in Med 2016; 37: E1–E32
GuidelinesE2
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
tion of giant tumors has been performed using (repeated or sin-
gle shot large volume) ethanol injection under general anesthesia
[16, 17, 62]. However, this technique has significant adverse ef-
fects and complete necrosis was difficult to achieve; this tech-
nique has been abandoned.
Location of tumors
HCC tumors in a subcapsular location or adjacent to the gallblad-
der have a higher likelihood of incomplete ablation [67] or major
complications [54, 68, 69]. In a study of 24 explanted livers with
RFA-treated HCC prior to liver transplantation, 88% complete ne-
crosis was achieved for tumors with a non-perivascular location,
compared to 47% complete necrosis for tumors with perivascular
locations, the suggested reason being the ‘heat sink’ phenomen-
on (blood flow in peritumorally located vessels may carry heat
away from the lesions) [58].
To reduce the number of complications, attention must be paid to
vulnerable structures close to the tumor or the ablation zone. This
applies to the porta hepatis, gallbladder, stomach, small intestine
and colon, all of which are particularly sensitive to thermal dam-
age [70, 71]. In case of subdiaphragmatic lesions, pulmonary,
pleural or cardiac heat damagemight occur, usually with only min-
or clinical significance [72, 73]. Subcapsular or exophytic tumors
should be accessed through a portion (≥10mm) of non-tumoral
liver tissue, whenever possible [74], since direct needle insertion
into the tumor carries a higher risk of complications, e. g. needle-
track seeding or hemorrhage [68]. In selected patients, some op-
erators are prepared to ablate even subscapular tumors [75, 76].
Number of tumors
The maximum number of tumors that can be ablated in a single
procedure is not clearly defined, but ranges from 3 to 5 in most
centers [16]. Overall survival is best for patients with solitary tu-
mors, intermediate for those with 2 to 3 tumors, and worst for
those with ≥3 tumors [77].
Recommendation 3
The maximum recommended diameter of HCC lesions treat-
able with thermal ablation is generally considered below or
equal to 5 cm, although optimal results are obtained in lesions
<3 cm (LoE 2b, GoR B). Strong consensus (100%).
Recommendation 4
The ablation zone should aim to extend at least 5mm beyond
the visible borders (LoE 3a, GoR B). Strong consensus (100%).
Recommendation 5
In lesions close to large vessels and heat-sensitive structures,
alternative or additional techniques should be considered
(LoE 3a, GoR B). Strong consensus (100%).
Recommendation 6
Three to five HCCs are the recommended maximum number
of lesions in a single session that allows percutaneous abla-
tion with curative intent (LoE 2a, GoR B). Strong consensus
(100%).
RFA versus surgical resection in small HCCs
There is inconclusive evidence as towhether RFA is as effective as
surgical resection as the first-line treatment for patients with
small, solitary HCCs [63–71, 78].
Randomized controlled trials (RCTs) report conflicting results
[79–81]. While the first did not identify outcome differences
[79], the others suggested survival advantages for surgical re-
section [80, 81]. Uncontrolled investigations have reported sim-
ilar outcomes for resection and RFA in early HCC patients [82].
In non-randomized comparative studies, hepatectomy was re-
ported to be better than percutaneous ablation [83], whereas
other studies reported no significant difference [84–86]. Higher
survival rates were found for resection [87]. A meta-analysis
including 11873 patients (n =6094 RFA; n=5779 hepatic resec-
tion) did not find significant differences between groups for 1-
and 3-year overall survival, recurrence-free survival and dis-
ease-free survival. The 5-year overall survival was lower with
RFA likely due to higher 3- and 5-year recurrence rates with
RFA, but the complication rate and hospital stays were signifi-
cantly lower for RFA patients [78]. Surgical resection significant-
ly improved the overall survival and disease-free survival rates
in comparison with RFA, but still, in a selected group of patients
(Child-Pugh class B, multiple HCCs, or in HCCs ≤3 cm) the two
treatments did not show significant differences [87]. This study
was not randomized and the surgical and ablation series were
obtained in different centers. In a randomized trial resection
had better survival and lower recurrence rates than RFA for pa-
tients with HCCs using the Milan criteria [80]. This analysis as-
sessed the role of specific tumor size thresholds in early HCC,
showing that size had a great impact on the effectiveness of
RFA but not of surgery.
A systematic review of 8000 patients [14] with a current Co-
chrane analysis [88] reported uncertainty regarding the ques-
tion of the impact of RFA versus surgery. However, a more re-
cent meta-analysis, published after the Cochrane analysis [89],
showed that there were differences in age and liver function be-
tween patients with early HCC submitted to either RFA or resec-
tion. When the analysis was corrected for these parameters, no
survival differences were observed between RFA and surgery in
single HCCs <2 cm or 2–3 HCC tumors <3 cm, whereas surgery
resulted in a longer survival in the case of single HCCs measur-
ing 2–5 cm [89]. With RFA, survival rates have been reported to
be 39.9–68.5 % at 5 years [59, 82, 90–93] and local tumor pro-
gression rates to be 2.4–16.9 % [59, 90, 91, 93]. Mortality and
morbidity rates of RFA have been reported to be 0–1.5% and
0.9–7.9 %, respectively [59, 82, 91–94].
Percutaneous ethanol injection
PEI was the first ablative procedure, initially reported in the early
1980 s [45, 46, 95]. Under US guidance the tip of a fine needle
(20–21 gauge) is placed inside the lesion. Ethanol is then injec-
ted. It creates a coagulative necrosis as a result of cellular dehy-
dration, protein denaturation, and chemical occlusion of small
tumor vessels [12, 83, 96–100].
The procedure is inexpensive and safe, with low mortality and
morbidity (0–3.2% and 0–0.4 %, respectively) [101–103]. Even
though RFA has replaced PEI because of superior and predictable
ablative results, the two methods are equally effective in small
tumors (< 2 cm) [43, 104, 105]. PEI can be offered in small HCCs,
mainly those for which RFA is not feasible due to tumor location
(e. g. adjacent to the gallbladder, hepatic hilum, or large vessels)
[106].
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Another chemical ablation technique, percutaneous acetic acid
injection (PAI), has not offered substantial advantages over PEI
[107].
RFA versus PEI
In comparison with PEI, the necrotic area in RFA is predictable
and must include a peritumoral safety margin ≥5mm of necro-
sis. This will ablate satellite tumors and minimize local recur-
rence.
Randomized controlled trials comparing RFA with PEI demon-
strate that RFA is superior to ethanol injection in terms of treat-
ment response, number of sessions, recurrences, and overall sur-
vival (2-year local recurrence rate: 2–18% versus 11–45%) [104,
105, 108–112] as further supported by meta-analyses [88, 111,
113].
A meta-analysis of six RCTs comparing RFAwith PEI and enrolling
patients with a tumor size of ≤5 cm found RFA significantly su-
perior to PEI with overall survival (HR 1.64, 95% CI 1.31 to 2.07),
and lack of local progression (HR 2.44, 95% CI 1.71–3.49) [88].
The efficacy of themethods is similar for tumors ≤2 cm [43, 104,
105, 114]. Meta-analyses, including RCTs, confirmed that treat-
ment with RFA offers a survival benefit as compared to PEI in tu-
mors > 2 cm [111–113, 115, 116]. RFA has a slightly higher rate
of major complications (4%; 95% CI, 1.8–6.4%) as compared to
PEI (2.7 %; 95% CI, 0.4–5.1%) [54, 108, 110, 116]. The best re-
sults obtained in series of HCC patients treated by RFA provided
5-year survival rates of 40–70% or higher in select groups of pa-
tients [60, 91, 117]. The best outcomes have been reported in
Child–Pugh A patients with small (< 2 cm) single tumors [82,
118]. Independent predictors of survival with RFA are initial
complete response, Child–Pugh score, number or size of no-
dules, and baseline alpha-fetoprotein levels [87].
Child–Pugh A patients with small tumors – that are expected to
achieve complete response – are the ideal candidates for RFA,
with few patients being more suitable for PEI [119].
Other procedures
Percutaneous microwave ablation (MWA), produced by dielec-
tric heat from microwave energy emitted from an inserted bi-
polar electrode, was introduced into clinical practice in the
1990 s [48, 56, 120–125]. The technique is reported to improve
local tumor control [48], with complete response rates of 89–
95% and three-year survival rates of 51–81% [48, 56, 123,
126–128]. An RCT demonstrated that the number of treatment
sessions was fewer with RFA than with microwave coagulation
[129], although the rates of complete therapeutic effect, major
complications, and local tumor progression were not statistical-
ly different between the two therapies. Although requiring elec-
trode needles of a larger diameter than with RFA, MWA has
been shown to be safe [130]. Differences in ablative capability
with different MWA needle types working at different frequen-
cies of emission are recognized, although no formal comparison
has been reported. This is at variance with RFA, where different
devices tend to produce similar ablation volumes [131]. An RCT
comparing MWA with RFA for HCCs <4 cm, showed 89% and
96% complete response rates, respectively, and 24% and 12%
for two-year local recurrence rates, respectively (differences
not statistically significant). The incidence of residual foci of un-
treated disease was significantly different (17.4% for MWA, and
8.3% for RFA) [129]. Laser thermal ablation is a further alterna-
tive, and is useful for HCCs <4 cm [11, 132–135]. This approach
is mainly used in Europe with experience from single centers
[11, 133, 134]. No trial was found for RFA versus placebo or for
transplantation.
Selection of ablation technique
With PEI, local response is related to tumor size. PEI has yielded
very favorable results for small encapsulated HCCs (< 2 cm) [17,
95]. Complete ablation can be achieved in 90–100% of tumors
< 2 cm, the percent of complete ablation is 70–80% for larger tu-
mors of 2–3 cm in size, and 50–60% for lesions larger than 3 cm
[119, 136]. HCC encapsulation by a cirrhotic liver prevents satel-
lite nodules from being reached, leading to higher rates of local
recurrence in comparison to RFA (10–33% in tumors smaller
than 3 cm and 44–50% in larger tumors [100, 137–139]). The
targeting of the necrosis only to intra-nodular tissue avoids pos-
sible damage to surrounding structures.
Recommendation 7
Percutaneous ethanol injection with curative intent is an al-
ternative to thermal ablation in encapsulated HCCs <20mm
(LoE 2a, GoR B). Broad agreement (95%).
Recommendation 8
Percutaneous ethanol injection can be an alternative in case of
contraindications to thermal ablation (LoE 3b, GoR B). Broad
agreement (79%).
Selection of imaging modality (ultrasound, CT, MRI)
US is the first-line imaging modality for local ablative procedures
in the liver (except for intraoperative cryoablation). CT guidance
can be an alternative, particularly when US guidance is not feasi-
ble anatomically or with US imaging of occult lesions [140, 141].
MRI guidance is possible but with limited availability. Local
expertise and personal experience determine the modality of
choice. Contrast-enhanced imaging must be available during the
interventional procedure to confirm the completeness of necro-
sis. Fusion imaging is an alternative technique that can be used
for the guidance of the procedure [16].
Planning and monitoring ablation treatment
Imaging plays an important role before, during and after ablation
procedures. Assessment of tissue perfusion is crucial to differ-
entiate necrotic areas from viable residual tumor. With US- and
CT-guided RFA, this requires evaluation with contrast-enhanced
imaging during and immediately after ablation. CEUS can provide
important information for assessment during and immediately
after ablation [142, 143]:
▶ assessment of the lesions to be treated by ablation (number,
size, degree and homogeneity of lesion enhancement, pres-
ence of feeding vessels, to define the eligibility for treatment
and the best ablation strategy)
▶ depiction of previously undetectable lesions with the support
of fusion imaging, enabling needle/probe guidance to occult
lesions
▶ detection of viable tumor persistence following loco-regional
treatment [66]
CEUS is themost effective method to define local recurrence in a
treated nodule because of its real-time capability, the intra-vas-
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cular characteristic of the contrast agent and the near-total dif-
ferentiation between the displayed contrast and background
information of current imagingmethods [8]. CT andMRI (3D re-
construction) provide better overviews of the liver and adjacent
organs, which are necessary for pretreatment staging and useful
to detect distant intra- and extra-hepatic tumor recurrence.
Contraindications
Contraindications to local ablation are identical to the general
contraindications to interventional procedures, based on the
risk and benefit for each individual patient and with particular
attention to the age, co-morbidity, and desires of the patient
[144–146]. Local ablative strategies are contraindicated in pa-
tients with significant ascites, uncorrectable coagulopathy, and
obstructive jaundice (because of the risk of bile peritonitis). A
predicted safe needle track must be confirmed.
Complications
Studies have established that RFA is a low-risk procedure [147–
150], with a mortality of 0.1–0.8 % and few adverse events. Ma-
jor complications occur in 2.2–11% of RFA-treated patients [94,
147, 151–153]. Bleeding, infection, fistula formation, bile duct
damage, and tumor seeding are possible complications of local
ablative therapy [16, 17, 23, 146]. Tumor seeding is reported
only for percutaneous procedures and is observed in 0–12.5 %
(median 0.9%) [154], mainly in PEI [74, 155–160]. Larger nee-
dle diameters, multiple punctures, subcapsular tumor locations,
and combination with biopsies are associated with a higher risk
[152].
Thermal track ablation should be performed at the conclusion of
any thermal ablation, as it reduces the likelihood of tumor seed-
ing to below 1% [74, 156–158].
Guidelines including RFA for HCC
European guidelines on HCC
EASL–EORTC Clinical Practice Guidelines: Management of HCC1
According to the European Association for the Study of the Liver
(EASL) and the European Organisation for Research and Treat-
ment of Cancer (EORTC) 2012 guidelines, local ablative proce-
dures for focal liver lesions (FLLs) are indicated for the following
situations [161]:
▶ RFA or PEI as the standard of care for patients with tumors
stage 0-A according to the Barcelona-Clinic Liver Cancer
(BCLC) staging system [162, 163], when not suitable for sur-
gery [Evidence 2A; Recommendation 1B].
▶ RFA is preferred over PEI, in order to assure better control of
the disease, corresponding to complete response with a safety
margin [Evidence 1D, Recommendation 1A]. PEI can be used in
10–15% where RFA is not technically feasible but PEI is prac-
ticable.
▶ RFA or PEI is equally acceptable for small tumors <2 cm classi-
fied as stage 0 tumors according to BCLC classification, with
proof that more than 90% of cases will have a complete re-
sponse and a good long-term outcome [Evidence 1A, Recom-
mendation 1C].
ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and
follow-up of HCC2
According to the European Society for Medical Oncology (ESMO)
and The European Society of Digestive Oncology (ESDO) guide-
lines [164], indications are:
▶ Local ablative techniques, including RFA and PEI as alternatives
to resection for treatment of small HCC nodules (<2 cm) [LoE
3, GoR B].
▶ RFA is recommended over PEI whenever it is available and fea-
sible, as it provides better local control, especially in HCCs
>2 cm [LoE 2, GoR A] [13].
▶ For RFA treatment, the number and diameter of lesions to be
treated should not exceed 5 and 5 cm, respectively [LoE 3,
GoR B].
▶ Dynamic CT and MRI examinations every 3 months for the
first 2 years and surveillance every 6 months thereafter are re-
commended and should be used in accordance with the clini-
cal setting to detect early recurrence [LoE 3, GoR A].
▶ Patients with recurrences following curative therapy may still
be considered for attempts at curative therapy.
American Guidelines on HCC
AASLD Management of HCC: An Update3
According to the American Association for the Study of Liver Dis-
eases (AASLD) updated guidelines [http://www.aasld.org/sites/
default/files/guideline_documents/HCCUpdate2010.pdf], indica-
tions are:
▶ Resection as the first option for patients with the optimal pro-
file according to BCLC staging system (Level of evidence II)
▶ Liver transplantation or ablation in patients with advanced
disease (Level of evidence II)
▶ Local ablation for patients who cannot undergo resection, or as
a bridge to transplantation (level of evidence II).
▶ Alcohol injection and radiofrequency are equally effective for
tumors < 2 cm. However, the necrotic effect of radiofrequency
ablation is more predictable in all tumor sizes and in addition,
its efficacy is clearly superior to that of alcohol injection in lar-
ger tumors (level of evidence I).
▶ For very early HCC, confirmation of the completeness of abla-
tion by RFA therapy is needed to prove the efficacy of the
method.
National Cancer Institute (NCI) of American Guidelines for HCC
The NCI recommends loco-regional ablative procedures to be
considered in patients who are not liver transplant candidates.
There are no strict indications and the risk and benefits are to
be compared with alternative treatment strategies [http://www.
cancer.gov/types/liver/hp/adult-liver-treatment-pdq].
1 In this guideline, the classification of evidence was performed according to
the National Cancer Institute: PDQ_Levels of Evidence for Adult and Pediatric
Cancer Treatment Studies. Bethesda, MD: National Cancer Institute (http://
cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/HealthPro-
fessional). The strength of recommendations was rated using a modified
GRADE system (level of evidence: A: high, B: moderate, C: low/very lowqual-
ity; grade of recommendation: 1 = strong recommendation and 2=weaker
recommendation).
2 In this guideline, levels of evidence and grades of recommendation are
rated according to the adapted Infectious Diseases Society of American-
United States Public Health Service Grading System for ranking recommen-
dations in clinical guidelines (quality of evidence I-III; Strength of Recom-
mendation A – C).
3 For classification of evidence an own grading system (I, II-1, II-2, II-3, III)
was used.
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Asian Guidelines on HCC4
Asian Pacific Association for the Study of the Liver (APASL) con-
sensus recommendations on HCC
According to the APASL, the recommendations are [50]:
▶ Local ablation is an acceptable alternative to resection for small
HCCs (<3 cm) in Child-Pugh class A cirrhosis [LOE 2b, GOR B].
▶ Local ablation is a first-line treatment of unresectable, small
HCCs with ≤3 nodules in Child-Pugh class A or B cirrhosis
[LOE 2b, GOR B].
In the clinical guidelines (EASL, AASLD, APASL [50, 161, 165]), RFA
is considered a second-line treatment after surgery, without docu-
mented evidence, knowing that patients treated with RFA tend to
be sicker, and have more advanced liver disease [166, 167]. An ex-
pert position paper from the Barcelona group suggested using RFA
as the first-line treatment for BCLC-0 patients, corresponding to a
tumor bulk of a single HCC <2 cm [168]. In case of single tumors
>3 cm, the rates of complete response with RFA alone decrease
progressively [55]. Under these circumstances, a combination of
percutaneous ablation with transarterial chemoembolization has
provided better recurrence-free survival, but a significantly better
survival rate was not demonstrated in comparison to individual
treatments [169, 170]. Three meta-analyses concluded that a com-
bination of TACE plus RFA is associated with a higher survival rate
than each procedure alone [171–173]. The quality of the evidence
was thought to be low [171] and none of the analyses considered
the toxicity of combined therapy.
The presence of multiple tumors represented the most frequent
indication for RFA [21, 79, 87, 174–180]. An advantage of abla-
tion is parenchyma sparing, a major benefit in HCC patients,
most of whom have a poorly functioning cirrhotic liver. Decision
making should always be a multidisciplinary exercise.
Initially, patients should be assessed for possible transplantation.
Those who are not transplant candidates are considered for alter-
native treatments, taking into account that the present interven-
tional ultrasound recommendations are specifically designed for
HCCs in liver cirrhosis and are considered only after liver trans-
plantation has been excluded.
Recommendation 9
Amultidisciplinary approach to assess patientswith HCC in liver
cirrhosis for possible transplantation is recommended prior to
alternative treatments (LoE 5, GoR D). Strong consensus (100%).
Recommendation 10
RFA with curative intent is an alternative, more cost-effective
technique in comparison to surgery in early HCC BCLC-0 (HCC
<2 cm) (LoE 2a, GoR B). Strong consensus (100%).
Recommendation 11
RFA with curative intent should be considered as a second-
line treatment in single HCCs 2–5 cm in Child-Pugh A pa-
tients, after the patient has been evaluated for surgical resec-
tion (LoE 2b, GoR B). Strong consensus (100%).
Recommendation 12
RFAwith curative intent should be considered as the first-line
treatment in Child-Pugh B patients with single HCCs <5 cm or
in patients with 2 or 3 HCCs <3 cm (LoE 2b, GoR B). Strong
consensus (100%).
Recommendation 13
Solitary HCCs >3 cm not suitable for surgery should be consid-
ered for combined loco-regional treatments (LoE 4, GoR C).
Broad agreement (95%).
Recurrence and adjuvant therapy
The benefits of local ablative techniques are limited by disease re-
currence, which varies between 4–60% depending on the size of
the ablated tumor and the approach used. Local tumor progres-
sion after PEI has been reported to be between 6–43%, depend-
ing on the tumor size. This limits the value of the procedure in le-
sions >3 cm, where higher local recurrence rates are documented
[101, 102, 137, 138, 181].
In various clinical studies, combinations of RFA with other treat-
ment modalities (TACE followed by RFA [182] or hepatic arterial
balloon occlusion during RFA [183]) have been attempted to
increase the ablated volume by reducing the cooling effect of
the blood flow. Although extension of the necrotic zone was
achieved, it is uncertain whether these combined treatments im-
prove the prognosis.
The long-term prognosis following surgical resection or RFA for
HCC remains disappointing, with a high recurrence rate (5-year
rate > 70%), mainly a consequence of ineffective adjuvant therapy
[50, 184–188]. The results of the STORM trial, a phase III ran-
domized, double-blind, placebo-controlled trial of 1114 patients
evaluating adjuvant sorafenib after resection or ablation, showed
no differences in recurrence-free survival, time to recurrence or
overall survival [189].
Colorectal cancer liver metastases
It is estimated that 50–60% of patients with colorectal cancer
(CRC) will develop liver metastases [190]. Estimates for five-year
survival after diagnosis of liver metastases vary between 17–
48%. Themost successful treatment for hepatic metastases is sur-
gical resection [9, 10, 36, 77, 191–197]. When CRC metastases
are confined to the liver, liver resection is indicated as a poten-
tially curative treatment whenever an R0 resection (curative re-
section) of all metastases is technically feasible [34, 35, 198].
However, approximately 50–70% of these patients will develop
recurrence [199].
Local ablative procedures with curative intent have a role in the
management of CRC liver metastases [9, 10]. Depending on the
size of the lesions, RFA may be performed alone or combined with
resection [200]. Several studies have demonstrated that RFA
achieved permanent local ablation of liver metastases and a 5-
year survival of 24% to 43% [201–205]. These results are compar-
able to surgery [36, 77, 191–197]. This is noteworthy as RFA pa-
tients generally have a poorer prognosis, partly as a result of higher
comorbidity than surgical candidates [31]. Local recurrence occurs
more frequently after ablation than with resection [9, 10, 206].
In a study comparing RFA and surgery in 482 patients with CRC liv-
er metastases, the overall survival (OS) and disease-free survival
(DFS) did not differ between the two groups in 226 patients with
4 The APASL guidelines used the Oxford Centre for Evidence-based Medicine
classification (LoE 1–5; GoR A-D; May 2010) [http://www.cebm.net/ox-
ford-centre-evidence-based-medicine-levels-evidence-march-2009].
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a single metastatic tumor <3 cm (RFA group 99 patients, resection
group 127 patients): the five-year OS and DFS rates were 51.1%
and 33.6%, respectively, in the RFA group and 51.2% and 31.6%,
respectively, in the resection group. In the 70 patients with a soli-
tarymetastasis ≥3 cm (RFA group: 14 patients; resection group: 56
patients), the DFS rates were significantly lower in the RFA group
(RFA group: 23.1%; resection group: 36.6%; P=0.01) [207]. Two
meta-analyses confirmed that surgery is superior to RFA with re-
gard to survival outcomes in patients with resectable CRC liver me-
tastases [208, 209]. However, an imbalance between characteris-
tics of patients allocated to both treatments makes it difficult to
draw definitive conclusions [210].
The first RCT on the efficacy of RFA combined with chemotherapy
versus chemotherapy alone was underpowered; RFA plus systemic
treatment resulted in significantly longer progression-free survival
(PFS) compared with chemotherapy alone [211].
Combination therapy resulted in an excellent overall survival of
30 months, also achieved in systemic chemotherapy alone (con-
trol arm) [211]. There are no prospective, controlled, randomized
studies comparing resection and local ablative procedures.
Recommendation 14
Percutaneous thermal ablation with curative intent is a sec-
ond-line alternative to surgery in patients with colorectal liver
metastases (LoE 2a, GoR B). Strong consensus (100%).
Recommendation 15
The maximum diameter of metastatic lesions treatable with
thermal ablation is generally considered ≤4 cm, although bet-
ter results are obtained in lesions <3 cm (LoE 5, GoR D). Strong
consensus (100%).
Recommendation 16
The ablation zone should aim to extend at least 10mmbeyond
the visible borders (LoE 5, GoR D). Broad agreement (94%).
Other liver metastases
Percutaneous thermal ablation or PEI may be a therapeutic op-
tion for neuroendocrine liver metastases [28, 29].
Renal malignancies treated with local ablative therapy
Introduction
The incidence and detection of asymptomatic renal masses has
increased over the previous 25 years, essentially as a conse-
quence of improved imaging technology and the improved un-
derstanding of the clinical-pathological behavior of renal cell car-
cinoma (RCC) [212–216]. The survival rate has improved as a
result of earlier diagnosis [213, 217–219]. Currently most renal
masses (61%) are incidental findings [220].
Possible treatment options for RCC are [221]:
▶ Surgery, either nephrectomy or nephron-sparing (open or
laparoscopic)
▶ Local ablative procedures (percutaneous or laparoscopic)
▶ cryoablation
▶ radiofrequency ablation
▶ microwave ablation (MWA)
▶ Active surveillance
Treatment options for RCCs are appraised below with regard to
age and performance status, history of previous partial nephrect-
omy, comorbidity factors, renal function, and staging.
Small masses
Standard therapy for small RCCs is nephron-sparing surgery. Lo-
cal ablative techniques have evolved into alternative procedures,
showing excellent results [222]. Active surveillance, an alterna-
tive option, can be suggested in poor surgical candidates, as his-
tologically confirmed small RCCs have a growth rate of 4mm per
year [223]. Active surveillance is currently not a standard option.
Tumors < 4 cm in diameter are ideal candidates for ablative tech-
niques. The volume to be treated should include a 5–10mm safe-
ty margin [224]. Most tumors <3 cm can be treated in a single ab-
lation session. Tumors between 3–4 cm in diameter can also be
successfully treated, although multiple ablation sessions may be
required [225–233].
Recommendation 17
Patients with RCCs <3 cm with significant surgical risk or re-
quirement for nephron-sparing strategy should be considered
for local ablative therapy (LoE 2b, GoR B). Strong consensus
(100%).
RCTs comparing surgery and local ablative therapy have not been
performed [221, 234]. Cancer-specific survival is similar for both
methods [235, 236]. The European and American Urological As-
sociations recommend thermal ablation as a treatment option
for patients with a T1 renal mass [237].
US techniques are recommended as the ideal imaging guide for
RFA [237].
Possible advantages of local ablative procedures are: (1) treatment
option for surgically unfit patients, (2) lower morbidity and mor-
tality, (3) shorter hospitalization time, (4) better parenchymal
sparing.
The presence of viable tumor in core biopsies following RFA in
about 47% of cases has been suggested [238], but others found no
viable tumor on biopsy after one year [239]. This remains contro-
versial, probably resulting from histological uncertainty in defin-
ing viability in core specimens, suggesting that frequent imaging
follow-up is necessary. Cryotherapy was performed laparoscopi-
cally (75%) and RFA was mainly performed percutaneously (84%)
[240], making comparison difficult.
Local recurrence-free survival following image-guided tumor ab-
lation is 87% [241]. The local recurrence of percutaneously per-
formed RFA is estimated at 2.5–14% [242]. Cancer-specific survi-
val of patients treated with RFA is comparable to patients treated
with surgery [227, 237, 243]. Both cryotherapy and RFA had a
higher risk of recurrence compared to partial nephrectomy
[244], but re-intervention is straightforward [227].
The rate of major complications for cryotherapy is 5%, which is
lower than for surgery [237], the most common complication
being hemorrhage [213] with 2% developing distant metastases
[237, 243]. Post-procedural ureteric strictures have also been
documented [237]. Cryotherapy is preferred over RFA in central
tumors in contact with the renal hilum or the ureter [245].
Systemic therapy for advanced RCC is increasingly used. Imaging
does not always accurately differentiate benign from malignant
disease [246]. Up to 25% of small (< 3 cm) kidney lesions are benign
[247], and as such, based on established oncologic standards, his-
tological confirmation is necessary prior to treatment with a de-
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structive technique. This standard is not always followed. In a
meta-analysis the rate of unknown histology was reported at 40%
(before RFA) and 24% (before cryotherapy) [248].
Recommendation 18
RCC histology should be obtained prior to ablation (LoE 4, GoR
C). Broad agreement (81%).
Contrast-enhanced US (CEUS) can be used for surveillance after
RFA of RCCs in order to detect local recurrence and to assess for
liver metastases [249]. CT of the thorax and abdomen is neces-
sary to exclude metachronous extrahepatic metastases. No RCTs
have been performed [250–252].
Recommendation 19
Contrast-enhanced ultrasound or CT or MRI should be per-
formed in the follow-up after RCC ablation, unless contraindi-
cated (LoE 4, GoR C). Strong consensus (100%).
Pancreas
At present, radical resection is the only option capable of improv-
ing long-term survival in the case of pancreatic cancer. This is pos-
sible in 20–30%, and after resection, the 5-year survival rate,
even in high-volume surgical centers and in combinationwith ad-
juvant therapy, does not exceed 30% [253]. Neoadjuvant strate-
gies are under evaluation. RFA of pancreatic ductal adenocarcino-
ma is based on encouraging experiences in other organs [241,
254], and is intended to be palliative for unresectable locally ad-
vanced adenocarcinoma [255–259].
RFA is performed under intraoperative US guidance during lapa-
rotomy [255]. Following RFA, there are controversial patient sur-
vival reports. In pancreas centers, RFA has become a palliative
treatment for tumor cytoreduction in a multimodality treatment
approach [257, 259–261]. A systematic review concludes that
RFA has a positive impact on survival [259]. A pretreatment biop-
sy is required [246].
Abscess drainage
!
US-guided percutaneous drainage of abdominal abscesses is a
well-established interventional procedure first described in 1974
[262] and is currently the first-line treatment approach for abdom-
inal abscesses.
Definition and classification
Differentiation between phlegmonous inflammation and absces-
ses is of importance for treatment guidance. Antibiotic treatment
is indicated for phlegmonous inflammation and for abscesses
< 1–3 cm, although the “minimal drainage size” of abdominal ab-
scesses is not established. An abscess is a pus-containing con-
fined collection, most often caused by bacteria. To be termed an
abscess, the fluid has to be viscous and surrounded by an inflam-
matory wall that develops as a result of effective host defense
[263]. Free contaminated or infected peritoneal fluid or loculated
collections represent a phase in the continuum of peritoneal con-
tamination/infection/empyema and are not termed an abscess
[264]. A classification of abdominal abscesses has been proposed
[●" Table 1] [265]:
Recommendation 20
Phlegmonous infections and small abscesses should be treat-
ed with antibiotics and require no drainage (LoE: 5; GoR: D).
Strong consensus: 100%.
Postoperative fluid collection
Fluid collections present on postoperative imaging, localized or
generalized (“free fluid”), are common and nonspecific which
may represent different pathological entities such as hematoma,
exudate, seroma, bilioma, lymphocele or an abscess. Fluid seen
on imaging is often not characteristic; any patient with a clinical
suspicion of an abdominal abscess should have a diagnostic as-
piration to guide further management. Sterile fluid collections
can become infected postoperatively, requiring diagnostic aspira-
tion and eventually therapeutic drainage.
Ultrasound (US)
US imaging is often the initial modality used in abscess delinea-
tion as it allows dynamic evaluation and real-time guidance of
needling. Depending on the contents, an abscess can be anechoic,
hypoechoic and even hyperechoic. CEUS can be helpful in differ-
entiating vascularized from avascular areas [266, 267].
Computed tomography (CT) and magnetic resonance
imaging (MRI)
CT is indicated in technically limited US examinations or inconclu-
sive results. CT often gives better anatomic details (exact location,
size, shape, organ relations) of fluid collections than US, although
there is no evidence to support this. An enhancing thickened wall
and the presence of gas indicates abscess formation.
Magnetic resonance cholangiopancreatography (MRCP) is indica-
ted in patients with biliary tree obstruction and leakage, e. g.
after surgery, but is not used as the initial investigation in the de-
tection of abdominal abscesses.
Diagnostic aspiration
A US-guided diagnostic puncture of a fluid collection with a fine
needle or a larger needle (dependent on the viscosity) can distin-
guish an abscess from a non-infected fluid collection.
Table 1 Classification of abdominal abscesses.
classification examples
visceral versus non-visceral hepatic versus subphrenic
primary versus secondary splenic versus appendiceal
spontaneous versus
postoperative
diverticular versus
peri-anastomotic
intra-peritoneal versus
retroperitoneal
tubo-ovarian versus psoas
simple versus complex complex:
– multiple (liver)
– multiloculated
– communication with bowel
(e. g. leaking anastomosis)
– associated with necrotic tissue
(pancreatic)
– associated with cancer
anatomical subphrenic, subhepatic, lesser
sac, paracolic, pelvic, interloop,
perirenal, psoas
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The aspirate should be examined for pus and consistency (thick
or liquid) and for debris, in order to guide further drainage strat-
egy. The aspirate should be sent for bacterial culture.
Recommendation 21
Diagnostic aspiration of a suspected infected fluid collection is
recommended (LoE 5, GoR D). Strong consensus (100%).
Puncture and drainage
The fundamentals of image-guided (percutaneous) treatment of
abscesses include drainage with a needle or catheter, plus lavage.
A description of the procedure can be found in text-books [268]
and in the EFSUMB Course Book [(www.efsumb.org/ecb/ecb-01.
asp)].
Catheter drainage versus needle aspiration
A meta-analysis of 5 RCTs comparing catheter drainage and re-
peated needle aspirations of liver abscesses demonstrated cathe-
ter drainage to be more effective, with higher success and shorter
time to achieve clinical improvement [269]. Studies of abdominal
abscesses of various etiology have shown good results with re-
peated needle aspiration in simple abscesses < 5 cm. In larger ab-
scesses catheter drainage performed better than repeat needle
aspiration [270–274].
With regard to the organs involved, an abscess of 5 cm in the liver
is small in comparison with a 5 cm abscess in the kidney or
spleen. Needle aspiration should be the initial approach, as this
is simple, causes less patient discomfort and avoids problems
related to drainage catheter care. This technique is preferred if
bowel loops need to be traversed for drainage. Catheter drainage
is indicated if needle aspiration fails after 2–3 attempts [270,
275]. Needle aspiration may still be performed after catheter dis-
placement.
Recommendation 22
Abscesses less than 5 cm in diameter can be treated with nee-
dle aspiration (LoE 2b, GoR B). Strong consensus (100%).
Recommendation 23
Catheter drainage is more effective than needle aspiration in
abscesses larger than 5 cm in diameter (LoE 1a, GoR A). Broad
agreement (89%).
Small or large catheters
Large bore 12–14F catheters were favored for abscess drainage
early in the development of this clinical application, but with ex-
perience [276], a typical abscess catheter is now 7–10F. No dif-
ference in outcome was seen in a study of intra-abdominal ab-
scesses treated with 7F pigtail catheters and 14F sump drain
catheters [277].
This reduction in catheter size can be attributed to: 1. The early
interventionalist was influenced by surgical traditions, where
large catheters were common; 2. Developments in catheter mate-
rial and construction allowing a larger inner diameter and im-
proved surface structure. Currently large catheters (> 10F) should
be reserved for complex abscesses containing thick pus and debris.
Recommendation 24
Catheters of 7–10F in size are recommended for the treat-
ment of most abscesses, regardless of abscess dimensions
(LoE 4, GoR C). Broad agreement (90%).
Recommendation 25
Large catheters (> 10F) should be reserved for complex absces-
ses with thick contents (LoE, 5, GoR D). Broad agreement
(90%).
Catheter introduction techniques: Trocar versus Seldinger
Two techniques are used for the insertion of a drainage catheter:
the trocar (one-step) technique and the Seldinger (two-step)
technique. Both have advantages and disadvantages and can be
performed with either a free-hand or needle-guided technique,
depending on the preference and experience of the operator.
There are no studies comparing the two techniques, probably be-
cause the methods are complementary rather than competitive
[●" Table 2].
Recommendation 26
The trocar technique is suitable in most circumstances using
catheters ≤10 F (LoE 5, GoR D). Broad agreement (93%).
Recommendation 27
The Seldinger technique is recommendedwhen access is diffi-
cult, for large catheters, and for catheter replacement (LoE 5,
GoR D). Broad agreement (86%).
Single versus double lumen
Double lumen catheters are not recommended since they com-
bine the negative features of large diameters and relatively small
lumens.
Recommendation 28
Double lumen catheters are not recommended (LoE 5, GoR D).
Broad agreement (94%).
Table 2 Advantages and disadvantages of trocar and Seldinger techniques.
trocar tech-
nique
seldinger technique
advantages – fast and
simple
– preferred when access is difficult
– introduction guided by transrectal
or trans-vaginal probes possible
– preferred when track dilatation and
catheter exchange is needed
– preferred technique for large
catheters
– preferred for cases in which
insertion is difficult
disadvan-
tages and
limitations
– not suitable
for large
catheters
– fluoroscopy may be necessary to
monitor the procedure
– time-consuming and complex
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Abscess cavity extension and complexity, fistula, and con-
trast injection (X-ray, CEUS)
Treatment planning requires careful assessment of the size, shape,
content and extent of the abscess, including identification of asso-
ciated fistulas. Fistulography (or abscessography, sinography) with
intracavitary injection of iodinated contrast media under CT or
fluoroscopic guidance has been the recommended technique. Di-
rect injection of US contrast agent through the needle or catheter
has been reported to facilitate confirmation of correct needle or
catheter position and allows evaluation of any communication be-
tween cavities in complex abscesses at the bedside [278–280].
Recommendation 29
Intracavitary CEUS may add value regarding needle and cath-
eter position, cavity morphology and presence of fistulas (LoE
4, GoR C). Strong consensus (100%).
Specific organs and locations
With respect to the specific location of intra-abdominal abscesses
(organ or cavity), a dedicatedmanagement strategy should be con-
sidered, but the basis for all percutaneous drainage remains iden-
tical: puncture, aspiration and irrigation.
Liver abscess
Pyogenic liver abscesses are often the result of biliary obstruction
caused by benign or malignant diseases with consequent cholan-
gitis. Abscess formation may also occur following microbe entry
into the liver via the portal vein (pyophlebitis) secondary to GI
tract infections (diverticulitis, appendicitis, chronic inflamma-
tory bowel disease, or post-operative infections). The microbes
may also enter the liver via the arterial system e. g. in osteomye-
litis or endocarditis. For percutaneous drainage, a transhepatic
access route is preferred for direct puncture to avoid spillage of
pus into the peritoneal cavity. Further imaging with US, endo-
scopic ultrasound (EUS), CT, or MRI is indicated to ascertain the
cause of the biliary obstruction. Intracavitary contrast injection
(X-ray or CEUS) into a hepatic abscess can demonstrate commu-
nication between the abscess and the biliary tree, which might
alter management strategy. Small amebic abscesses generally re-
spond to conservative treatment and do not require drainage, but
large amebic abscesses may need drainage [281].
Recommendation 30
The origin of liver abscesses should be investigated to search
for an underlying cause (LoE 5, GoR D). Strong consensus
(100%).
Recommendation 31
A transhepatic access route is recommended for the percuta-
neous drainage of hepatic abscesses (LoE 5, GoR D). Strong
consensus (100%).
Splenic abscess
Splenic abscesses are rare, except in immunocompromised pa-
tients. There are no studies of percutaneous drainage versus sur-
gical treatment (splenectomy). The outcomes of percutaneous
drainage are conflicting; a meta-analysis [282] reported that per-
cutaneous drainage and needle aspiration had low success rates
(51% and 65%, respectively). Other studies reported a higher suc-
cess rate of percutaneous drainage [271, 283–289], which is re-
commended as the first-line treatment. Percutaneous treatment
allows preservation of the spleen. Splenic puncture or biopsy is
relatively safe as documented in a meta-analysis [290].
Recommendation 32
Percutaneous splenic abscess drainage should be the first-line
treatment and surgery should be performed in the case of
treatment failure (LoE 4, GoR C). Broad agreement (89%).
Pancreatic abscess
Percutaneous drainage of pancreatic abscesses is often prolonged
andmay require multiple catheters. A study has reported success
in 86% of patients [291, 292]. Typically pancreatic abscesses ap-
pear after acute pancreatitis. Fistulas can be problematic. The
percutaneous approach has the advantage of being quick and of-
fering treatment access for severely ill patients. As a second stage
procedure, conversion to internal drainage (double pigtail plastic
stent or self-expanding metal stents) via an EUS approach should
be considered [293]. However, this approach remains controver-
sial [294].
Recommendation 33
Pancreatic abscess management is complex and often pro-
longed. EUS and percutaneous procedures should be consid-
ered (LoE 4, GoR C). Broad agreement (89%).
Enteric abscess
Abscesses are frequent complications of Crohn´s disease, diverticu-
litis and appendicitis. In Crohn´s disease, there is no study compar-
ing percutaneous and surgical drainage of abscesses. Percutaneous
drainage of Crohn´s-related abscesses has a high success rate, dem-
onstrated in several studies and is the first-line treatment [295,
296]. With early percutaneous drainage, (non-elective) surgery
can often be avoided (14–85% of patients) [296–300].
Several studies suggest that percutaneous drainage of Crohn’s-
related abscesses is less effectivewhen there are associated bowel
(macro) fistulas [295]. A fistula should be suspected when the
drainage catheter produces a persistently high volume of fluid
(> 50mL of fluid per day). Contrast injection (X-ray or CEUS) into
the abscess (fistulography) should be performed.
Abscesses can be detected in 15% of patients with acute diverti-
culitis [301, 302]. Antibiotics successfully treat smaller abscesses
(< 3 cm) [301, 303, 304], but larger abscesses (>3 cm) require per-
cutaneous drainage [305, 306]. In peridiverticular abscesses, sus-
pected fistulas need to be confirmed or refuted as this may re-
quire surgery. Peri-appendicular abscesses can occur either as a
result of rupture of an infected appendix or post-operatively. De-
spite the frequency of peri-appendicular abscesses, no studies
have investigated percutaneous treatment.
It is generally accepted that a peri-appendicular abscess will re-
spond to percutaneous treatment. A pitfall with presumed peri-
appendiceal and peri-diverticular abscesses is an infected, necrotic
tumor. This may be drained successfully but requires subsequent
colonoscopy to determine if an underlying tumor is present. Leak-
age of enteric contents at an anastomosis may lead to abscess for-
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mation which most often requires reconstructive surgery. Some-
times, a non-surgical approach is preferred with usage of long-
term percutaneous drainage with large catheters.
Recommendation 34
Abscesses in Crohn´s disease, diverticulitis and appendicitis
may benefit from percutaneous drainage as the first-line
strategy (LoE 4, GoR C). Broad agreement (89%).
Abscess in the lower abdomen and pelvis
Abscesses located in the lower abdomen and pelvis represent a
challenge primarily because of overlying bowel loops, making
the traditional transabdominal puncture route difficult. For these
deep pelvic abscesses, alternative puncture routes are available.
Transrectal, transvaginal, transperineal and transgluteal accesses
have all been shown to be useful and safe [272, 293, 307, 308].
The transrectal route provides direct access to perirectal and pre-
sacral fluid collections whereas the transvaginal route accesses
gynecologic and midpelvic collections. The development of dedi-
cated endoprobes with needle guides has established transvagi-
nal and transrectal US-guided abscess drainage procedures [293]
but comparative studies are missing. Different drainage tech-
niques are possible (needle aspiration or catheter drainage) and
catheters can be introduced using a one-step trocar technique or
preferably using a Seldinger technique [272, 307, 308].
Recommendation 35
US-guided drainage by transrectal, transperineal or transvagi-
nal access is associated with a low risk of complications and
should be considered for deep pelvic abscesses (LoE 4, GoR
C). Strong consensus (100%).
Catheter management and patient care during abscess
drainage
There is a paucity of evidence for the management of abscess ca-
theters and this mainly depends on clinical judgment and local
practice. Daily catheter care, including routine irrigation, and ob-
servation of output is mandatory for successful abscess drainage.
There is general agreement regarding catheter management:
▶ An abscess catheter should be connected to a drainage bag.
▶ Routine irrigation should be performed at least 3 times a day.
▶ Irrigation with 10–20mL of saline solution until the aspirate
is clear is often sufficient; over-distension should be avoided.
▶ A persistently high output (> 50mL of fluid per day) may indi-
cate connection to a fistula.
▶ Re-evaluation with US, CT or fluoroscopy is indicated in cases
of catheter dysfunction or insufficient drainage.
▶ Repeated catheter clogging indicates a change (over guide
wire) to a new and possibly larger catheter.
▶ Simple abscesses are typically alleviated after 5–7 days of
treatment indicated by a decreased output (< 10mL of fluid
per day) and clinical improvement.
Use of fibrinolytics (plasminogen activator or streptoki-
nase) in viscous fluid collections or complex abscesses
Two studies suggest that routine catheter flushing using fibrino-
lytics instead of saline solution decreases the total time to abscess
resolution, length of hospital stay, and total cost of care [309,
310]. No improvement after streptokinase in the treatment of
pleural infections was reported [311].
Recommendation 36
Use of intracavitary fibrinolytics is not routinely recommen-
ded (LoE 5, GoR D). Broad agreement (94%).
Microbiology and antibiotics
Intra-abdominal abscesses are often polymicrobial (mixed aerobic
and anaerobic) reflecting mixed gut flora [312–314], whereas liv-
er and splenic abscesses tend to be monomicrobial. These absces-
ses generally require a combination of drainage (percutaneous/
surgical) with antibiotics for complete cure, since antibiotics do
not reach sufficient concentrations within the abscess cavity, as
evidenced in an experimental study [315]. Antibiotics are recom-
mended for patients who present with clinical signs of bacteremia
(e. g., fever and leukocytosis). Antibiotic treatment should (when
indicated) be targeted according to the culture results and antibio-
tic sensitivities. If required, broad-spectrum antibiotic agents are
recommended as initial treatment, accounting for the polymicro-
bial nature of abdominal abscesses. Further refinement of antibio-
tics should be based on culture data including sensitivity testing
[313, 316].
Intracavitary antibiotic treatment
Intracavitary antibiotic treatment is not recommended in the
treatment of abdominal abscesses.
Peri-interventional antibiotic treatment
Peri-interventional use of antibiotics should be reserved for pa-
tients who present with clinical signs of septicemia at the time
of the drainage procedure [313]. There is no evidence for the pro-
phylactic use of antibiotics.
Specimen collection
It is good clinical practice to collect pus/aspirate material prior to
antibiotic treatment, to ensure sufficient samples for chemical,
cytological, and microbiological tests.
Ultrasound-guided paracentesis
!
Background
Fluid collection within the peritoneal cavity is multi-factorial: hy-
persecretion of serous fluid by the peritoneumwith impaired fluid
absorption (e. g. peritonitis), injury to fluid-containing structures
and pressure alterations in the venous system (e. g. right heart fail-
ure, portal hypertension) [268].
Paracentesis is performed either as a diagnostic or as a therapeu-
tic procedure, in the presence of ascites or suspected bacterial
peritonitis. Therapeutic paracentesis provides almost immediate
symptomatic relief and is usually well tolerated.
Technical issues
Ascites drainage is usually easily and safely performed by inserting
a 14–18 gauge needle (including paracentesis-specific devices) or
as a one-step catheter under US guidance. Catheters can be pig-tail,
they can have an internal string for internal loop fixation, or an in-
ternal balloon fixation can be used. A small bore catheter (between
5F and 7F) is usually adequate.
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One-step catheters are excellent for drainage but are difficult to
introduce as they will not penetrate tissue as easily as a 21–23
gauge needle, particularly if the tissue is fibrous or firm. Conver-
sion of the procedure to a Seldinger technique using a lumbar
needle with the catheter being placed over a guidewire as the fi-
nal step is possible. Once positioned correctly, the catheter should
be secured and left in place for several hours to allow fluid drain-
age [268].
US guidance offers real-time imaging of the needle tip and sur-
roundings during the procedure, making it safe and effective. In
most instances, US assistance (i. e., US utilized to select the best
access point prior to blind needle insertion) is as safe as US gui-
dance [317].
US helps to reduce the risk of injury to vessels that run along the
inner abdominal wall (e. g. inferior epigastric vessels, distended
paraumbilical veins) and tominimize failed aspirations due tomal-
position of the needle tip. It adds more options to the traditional
puncture site in the lower left quadrant of the abdomen (reverse
McBurney point). The needle may be inserted anywhere; the op-
erator should choose the shortest possible route that avoids obsta-
cles such as blood vessels, the omentum, and the bowel. The ability
to use it as a bedside procedure is an important additional advan-
tage [318].
Complications
Paracentesis is considered a safe procedure, carrying a 1% risk of
overall complications, which include leakage of ascitic fluid, local
infection, abdominal wall hematomas, intraperitoneal hemor-
rhage, and intestinal perforation [319]. It is recommended to fol-
low strict antiseptic practices in all patients [320]. Ultrasound
guidance can reduce the risk of complications after paracentesis,
such as pneumothorax and bleeding, thus improving safety [317,
321].
Cytology, microbiology tests
Fluid can be sent for relevant chemical, cytological, andmicrobio-
logical tests. The ideal volume for Gram stain is 0.5mL and 2mL
for most cultures. A culture for mycobacteria requires a larger
volume of approximately 10mL. A sterile tube (or even the as-
piration syringe itself) is sufficient for dispatch to the microbiol-
ogy laboratory, when the transportation time is < 2 hours. If the
transport time will exceed 2 hours, a suitable transport medium
must be used. If collected specimens cannot be submitted imme-
diately, the fluid should be stored at 4 °C to prevent specimen
contamination or overgrowth by fast-growing organisms [268].
Recommendation 37
Ultrasound-guided or assisted paracentesis is a low-risk and
effective procedure (LoE 4, GoR C). Strong consensus (100%).
Specific considerations
Cirrhosis
Ascites is the most common complication of cirrhosis leading to
hospital admission. 12% of hospitalized patients who present
with decompensated cirrhosis and ascites have spontaneous bac-
terial peritonitis (SBP). Early paracentesis is recommended for all
hospitalized patients with cirrhosis with a large amount of ascites
of recent onset or worsening ascites not responding to diuretic
therapy or, when there is fever or abdominal pain, to rule out SBP
even when the ascites is scanty. To demonstrate SBP, the white
blood cell count in the fluid (>500 leucocytes/nL or >250 granulo-
cytes/nL) and/or microbiologic testing positive for bacteria can be
used [322].
Albumin administration
Large-volume paracentesis (> 5 L) is generally an effective and
safe procedure, but it does carry a risk of “postparacentesis circu-
latory dysfunction” (PCD). Even before paracentesis, patients
with ascites are subject to marked circulatory dysfunction. In
the majority of patients not receiving adjunctive treatment, re-
moval of large volumes of ascites by reducing intra-abdominal
pressure increases venous return, which increases cardiac output
but also favors further transfer of circulating fluid into the perito-
neal cavity. However, because of the drop in peripheral vascular
resistance and increase in fluid accumulation in the peritoneal
cavity, the effective circulating volume declines, leading to a re-
duction in arterial pressure and activation of the renin-angioten-
sin-aldosterone pathway. This complication is associated with a
high rate of re-accumulation of ascites, development of hepator-
enal syndrome, dilutional hyponatremia, and a decrease in survi-
val. To alleviate PCD, albumin should be administered intrave-
nously in an amount of 6–8 gr for each liter of ascites fluid
removed, at least for paracentesis exceeding 5 liters in volume
[323].
Recommendation 38
Administration of albumin is mandatory in large-volume (> 5
liters) paracentesis (LoE 1a, GoR A). Strong consensus (100%).
Hemorrhagic complications
Bleeding complications after paracentesis are rare. Signs and
symptoms of hemorrhage typically become evident immediately
to 24 hours after the procedure. Renal dysfunction was the most
prevalent metabolic derangement, occurring in 70% of patients
with bleeding, compared to coagulopathy and thrombocytopenia
(59% and 8%, respectively) [319]. There is no recommendation
for the administration of coagulation factors or platelets. If blood
is found on diagnostic paracentesis, an abdominal CTor US exam-
ination should be performed to evaluate for abdominal wall he-
matoma or intra-abdominal bleeding. Patients with risk factors
for hemoperitoneum may benefit from either a lower-volume
paracentesis, slower drainage of ascites, or concurrent adminis-
tration of albumin [324].
Recommendation 39
There are no established preprocedural threshold coagulation
levels that preclude paracentesis (LoE 5, GoR D). Broad agree-
ment (94%).
Palliative paracentesis for malignant ascites
Malignant ascites accounts for around 10% of cases and occurs
with a variety of neoplasms, particularly breast, bronchus, ovary,
stomach, pancreas and colon [325]. Large amounts of ascites can
cause increased abdominal pressure with pain, dyspnea, loss of
appetite, nausea, and reduced mobility. Long-term paracentesis
is indicated for patients with symptoms of increased intraab-
dominal pressure caused by recurring malignant ascites despite
repeated paracentesis.
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There is no consensus on the speed of fluid withdrawal, and con-
current intravenous hydration is not well standardized [326].
Tunneled or non-tunneled or peritoneal catheters may be placed
under US and fluoroscopic guidance. The use of non-tunneled
drainage catheters is associated with increased infection (35%),
blockage (30%) and leakage (20%) and should be considered in
patients with a short life expectancy [327, 328]. Several studies
have described successful and safe placement of tunneled perito-
neal catheters as well as the PleurX™ catheter in patients with
malignant ascites and a longer life expectancy [329–335]. A
study comparing 40 patients with abdominal catheters and 67
patients who underwent repeated large-volume paracenteses
over a 41-month period found similar complication rates. Patient
satisfaction with the catheter was high [336]. A systematic re-
view shows that the peritoneal catheter drainage system is clini-
cally effective in patients with malignant ascites, has low compli-
cation rates, improves quality of life and is less costly than
repeated inpatient paracentesis. A National Institute for Health
and Care Excellence (NICE) guideline recommended considera-
tion of a peritoneal catheter drainage system in patients with
treatment-resistant, recurrent malignant ascites [337].
Recommendation 40
Permanent catheter drainage should be considered for term-
inally ill patients with refractory ascites (LoE 4, GoR C). Broad
agreement (94%).
Sclerotherapy of non-parasitic cysts
!
Hepatic cysts
Hepatic cysts have a prevalence of 2.5–7%. Most are asympto-
matic and do not need treatment [338]. Percutaneous treatment,
consisting of aspiration of cystic fluid followed by injection of a
sclerosing agent, is usually performed with US guidance, as a
minimally invasive option for large or symptomatic cysts.
Indications
Large cysts (> 6–10 cm) which are symptomatic (pain or infec-
ted), causing space-occupying effects (abdominal distension, ob-
structive jaundice or both), require treatment. Other less estab-
lished indications include symptomatic small sub-capsular cysts
located at sites exposed to mechanical stress (beneath the ribs or
sternum) [339]. In polycystic liver disease, any dominant cysts
may be treated if causing symptoms or to avoid complications
(e. g., rupture, bleeding) [340–345].
Recommendation 41
With symptomatic or compressive hepatic cysts, percuta-
neous sclerotherapy or surgery should be considered (LoE 4,
GoR C). Broad agreement (96%).
Contraindications
Caution is required when treating hydatid cysts; the nature of a
cyst may not be known prior to aspiration [339]. When there is
communication with the biliary tree, cysts are usually decom-
pressed and not distended. A relative contraindication is he-
morrhagic cysts [346] though they can be treated with similar
results once infection or malignancy has been excluded [342].
Ascites and planned liver transplantation are other relative con-
traindications.
Other imaging modalities in the work-up (CT/MR/CEUS)
CT-guided puncture can also be performed but this is rarely nec-
essary as US-guided drainage is usually successful. Before sclero-
therapy is attempted, communication with the biliary tree
should be investigated using fluoroscopy or intracavitary admin-
istration of a US contrast agent [347, 348].
Multidisciplinary decision making
Multidisciplinary decision (gastroenterologists, surgeons, inter-
ventional radiologists) for the procedure is obligatory as other
options include open surgery and laparoscopic deroofing which
are effective treatments. These treatments are associated with
substantial morbidity and mortality and require expertise [349,
350]. Percutaneous treatments have similar efficacy, allowing
surgery to be reserved for complicated cases or if percutaneous
sclerotherapy fails [341, 351].
Sclerotherapy versus surgery (fenestration)
No randomized prospective study comparing fenestration and
sclerotherapy has been published. In most centers, sclerotherapy
is attempted first as a noninvasive option, and laparoscopic fe-
nestration is indicated in refractory cases [351].
Recommendation 42
Percutaneous ethanol sclerotherapy is a good alternative to la-
paroscopic deroofing with similar efficacy and lower compli-
cation rates (LoE 4, GoR C). Broad agreement (96%).
Prognosis
The majority of patients who undergo percutaneous sclerother-
apy are symptomatically improved immediately following the
procedure, but only 20% will have partial or full regression of
the dominant and symptomatic cyst [350]. In polycystic liver
disease both sclerotherapy and surgery are disappointing (77–
100% recurrence rate) [9].
Materials and technical issues
The treatment consists of evacuation of the cystic contents (ei-
ther by aspiration or drainage via a catheter) followed by sclero-
therapy of the inner epithelium using standard agents (etha-
nol, polidocanol, tetracycline chloride, minocycline chloride,
hypertonic saline solution and ethanolamine oleate) [352–
356]. Following local anesthesia, a Chiba needle (18–20 gauge)
is introduced into the cyst under US guidance and advanced into
the distal third of the cyst. One aliquot should be aspirated for
cytologic analysis, white blood cell count, microbiology, and bi-
lirubin level. If the fluid is clear or amber-colored, biliary tree
communication is unlikely, thus allowing aspiration and sclero-
therapy to proceed. A yellowish or dark-greenish color suggests
a biliary communication; these cysts should first be aspirated
and drained [339]. A radiopaque contrast medium or US con-
trast agent should be instilled into the cyst to exclude a connec-
tion with the biliary tree [347]. If contrast medium enters the
bile ducts, sclerotherapy is contraindicated.
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Ethanol sclerotherapy
Ethanol is most commonly used for sclerotherapy of hepatic cysts
(95–98% concentration) [357–359]. Single or multiple sessions
may be needed with evacuation of the fluid content performed
using 6–8F catheters or a Chiba needle (18–20 gauge) [357–359].
Catheters may be introduced directly using the trocar technique
with low complications. Prolonged catheter drainage with nega-
tive pressure and single-session alcohol sclerotherapy had sim-
ilar results in hepatic cysts. Performing sclerotherapy in one ses-
sion might be less effective for destroying the entire epithelium
in comparison with prolonged drainage [338]. In ethanol sclero-
therapy, different volumes (10–50% (as a rule “30%”) of the cyst
volume, total volume <200ml), different ethanol concentrations
(95–99%) were used and the sclerosing agent exposure time var-
ied from 10 minutes (as a rule “30 minutes”) to 4 hours [352,
360]. The longer the sclerosing time (retention time, reinjec-
tions), the lower the recurrence rate but the higher the complica-
tion rate. After ethanol sclerotherapy, an 80–100% reduction of
cyst volume may be achieved [338, 341, 352, 357, 359, 360].
The main complications during ethanol sclerotherapy are pain,
ethanol-induced fever or hyperthermia, intoxication, intra-cystic
bleeding and iatrogenic pleurisy or peritonitis [342, 353]. Active
bleeding can be controlled by repeat injection of the sclerosing
agent [339]. Ethanol intoxication and even ethanol-induced
coma are serious events that may occur when a large volume of
ethanol is injected into large cysts or when the exposure time to
ethanol is > 60 minutes, i. e., the time interval that is optimal for
a sclerosing effect [338, 342]. Patients are often hospitalized for
24h and sedation may be necessary.
Recommendation 43
With percutaneous ethanol sclerotherapy of large liver cysts,
the use of small catheters instead of needles should be consid-
ered to achieve a longer ethanol exposure time (LoE 4, GoR C).
Broad agreement (95%).
Sclerotherapy using other substances
Several other substances with better safety profiles, ease of use
and low cost have been tested with good results and few compli-
cations [352–356]. Polidocanol 1–3% (aethoxysklerol) may be
preferred for its local anesthetic properties (it is less painful
than alcohol) and its slight bactericidal activity [339].
The technique usually consists of evacuation of part of the cyst
contents, followed by instillation of the sclerosing agent, which
is left in situ for various time periods. The intra-cystic distribu-
tion of the sclerosing agent may be enhanced by using foam
sclerosants (liquid sclerosants mixed with air). The advantage of
foam sclerotherapy with polidocanol (10mL of 3%) has been
demonstrated with hepatic cysts [347, 361].
Recommendation 44
Percutaneous sclerotherapy using other substances is an alter-
native to ethanol (LoE 4, GoR C). Broad agreement (90%).
Ultrasonographic follow-up
In polidocanol therapy maximum volume reduction occurred
1 year after the procedure [347]. Follow-up examinations may
only be necessary in symptomatic patients.
Renal cysts
Indications
Simple renal cysts are mostly asymptomatic and do not require
treatment. In 2–4% the cyst may become symptomatic because
it enlarges or develops complications such as hemorrhage, infec-
tion, rupture or compression [362]. Cysts that develop adjacent to
the renal hilum may obstruct the urinary tract [363]. Sponta-
neous, iatrogenic or traumatic rupture of a large renal cyst may
cause hematuria or pain. US-guided cyst aspiration with or with-
out sclerosing therapy is a minimally invasive, simple, safe and
low-cost procedure [363].
Recommendation 45
Symptomatic simple renal cysts should be considered for
treatment. (LoE 4, GoR C). Broad agreement (94%).
Multidisciplinary decision making
A multidisciplinary decision regarding procedure choice is re-
commended as surgical excision via open, percutaneous, laparo-
scopic or robotic surgery is effective but more invasive. Laparo-
scopic deroofing achieves better results than percutaneous
sclerotherapy (PS) [362, 363]. Surgery carries a higher morbidity
and longer hospital stay, and is reserved for PS failures or for
atypical cysts. An RCTof 40 symptomatic renal cysts found percu-
taneous aspiration and sclerotherapy with polidocanol equal in
efficacy with lower morbidity and shorter hospital stay in com-
parison with laparoscopic deroofing [364], supporting results
from retrospective studies [365]. Percutaneous therapy is indica-
ted in nearly all symptomatic patients, with the exception of sus-
pected malignancy.
Recommendation 46
The decision on treatment modality should consider that per-
cutaneous sclerotherapy is less invasive and associated with
lower risks than laparoscopic deroofing, but has lower efficacy
(LoE 2b, GoR B). Broad agreement (88%).
Contraindications
Contraindications of renal cyst sclerotherapy are uncorrectable
coagulopathy, lack of a safe percutaneous access route, atypical
cystic masses where tumor is a possibility and communication
with the urinary tract that should be investigated with a contrast
study, either CEUS or with X-ray contrast material.
Other imaging modalities in the work-up (CT/CEUS)
Safe guidance of sclerotherapy of renal cysts may be performed
with contrast-enhanced CT [366] or US guidance combined with
fluoroscopy or CEUS [279]. Preconditions are:
▶ the possibility to assess any communication between the cyst
and the pelvicalyceal system by filling the cyst with contrast
medium (for US guidance this will be performed using fluoro-
scopy or intracavitary CEUS),
▶ to exclude any leakage from the puncture site into the retro-
peritoneal cavity [366].
Materials and technical aspects
A variety of substances are used for sclerotherapy of the urothe-
lium [356, 367–376] as described for liver cysts. Sclerotherapy is
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contraindicated if the contrast medium enters the collecting sys-
tem. To prevent pain, an anesthetic may be injected into the cyst
prior to the instillation of the sclerosing agent [377].
Simple cyst drainage without sclerotherapy
After simple aspiration, the recurrence ranges from 30–80%
[274, 377].
Recommendation 47
Simple aspiration should not be used in the treatment of renal
cysts because recurrence is frequent (LoE 4, GoR C). Broad
agreement (93%).
Ethanol sclerotherapy
The most common sclerotherapy agent for renal cysts is ethanol
[372–376]. A concentration of 95–99% destroys the secreting
cells of the cyst wall without affecting the renal parenchyma
[362]. Single or multiple sessions have been used, with better re-
sults but with higher complications for multiple sessions [363,
366, 373–377]. The time of exposure (in-dwell time) to ethanol
varies from 3 minutes to 4 hours, most often around 20 minutes
[352, 363, 373, 375, 377, 378]. The volume of ethanol injected fol-
lowing aspiration varies from 20–50% of the cyst volume and the
maximum dose from 75–200mL. Most studies use <100mL of
ethanol [362]. Several techniques have been evaluated to deliver a
higher ethanol concentration along the entire cyst wall (limiting
recurrence): use of a three-way tube to prevent air from entering
the renal cyst, repetition of fluid aspiration to reduce the presence
of debris adherent to the cyst wall [379], continuous-negative
pressure catheter drainage [338], continuous drainage of the cyst
for 24h before therapy [380] and no drainage of the agent after fin-
ishing the procedure [381]. The results are better for smaller cysts,
for two or more injection techniques and for continuous drainage
[363, 372–374].
The main complications that may occur during ethanol sclerother-
apy are pain, fever, and systemic reactions [362]. Alcohol intoxica-
tion is a rare complication, occurring after large volume injections.
Other complications include extravasation of the sclerosing agent
and bleeding, the latter being encountered more frequently after
rapid percutaneous drainage [362].
Recommendation 48
Multiple sessions and/or prolonged drainage should be used
to reduce recurrence in symptomatic large renal cysts treated
with ethanol sclerotherapy (LoE 4, GoR B). Broad agreement
(87%).
Ultrasonographic follow-up
Follow-up examinations may only be necessary in symptomatic
patients.
Abdominal echinococcal cysts, puncture, aspiration,
injection and re-aspiration (PAIR)
!
Introduction
Echinococcosis is a chronic, complex and neglected zoonosis with
widespread global distribution. 70% of cases of cystic echinococco-
sis (CE) are located in the liver [382]. US has an important role in
the diagnosis, staging and follow-up of abdominal CE and is estab-
lished in the interventional treatment of abdominal CE [383, 384].
Classification
The WHO echinococcal cyst classification [385, 386] is US-based
and was introduced to guide treatment options and to predict
prognosis [387]. Type CE1 and CE2 are the typical active cysts.
Type CE1 is unilocular, whereas CE2 is multilocular with daugh-
ter cysts. The Gharbi classification is still widely used [388]. How-
ever, only 28.8 % of publications included in a systematic review
used one of the standardized ultrasound classifications [389].
Diagnosis and differential diagnosis
Determining whether a cystic lesion is a “hydatid cyst” depends
on the presence of a thick wall or whenmembrane detachment is
obvious. Simple or minimally complex cysts, as well as biliary cy-
stadenocarcinomas or abscesses may have these features and
have to be considered in the differential diagnosis.
Imaging
US is the imaging modality most appropriate for diagnosis and dif-
ferential diagnosis [386], while US guidance is usually used for in-
tervention [390, 391]. CT is indicated when US is unsatisfactory
(obese patients, difficulty in imaging due to gas/bone) [392]. MRI
is usually not indicated as a guidance method for intervention but
is preferred to CT for pretreatment assessment because it charac-
terizes the internal structures of CE better [383, 393, 394].
Serological tests
Serological tests for echinococcosis should be obtained, where
available, before the procedure [395, 396].
PAIR indication
PAIR is most appropriate for Gharbi type I and II cysts (CE1 and
CE3(A) according to the WHO classification) [396, 397].
Relative contraindications
Hydatid cysts with multiple daughter cysts and solid compo-
nents (Gharbi Type III-IV and WHO CE2-CE3b) are not suitable
for PAIR [384, 397, 398]. It is reported that aggressive percuta-
neous evacuation for these complex cysts is useful, but is not
widely accepted.
Pretreatment procedures
As with any interventional procedure, before the PAIR procedure,
the patient should be carefully evaluated. Albendazole should be
started one week (or at least one day) prior to the procedure for
prophylaxis against abdominal contamination [399], and there-
after continued for at least one month [384, 400]. In one small
RCT, adjuvant albendazole treatment decreased the recurrence
rate in CE patients treated with PAIR [399].
Procedure, puncture and drainage
The procedure consists of puncture, aspiration, injection and re-as-
piration [268, 387, 401] using a 20-gauge fine needle [402, 403].
The cyst should not be punctured directly but via intervening liv-
er parenchyma to prevent spillage of the contents into the perito-
neum. Hydatid fluid is usually transparent. However, in aged or
infected cysts, the color may be dark yellow and the material vis-
cous. The aspirated fluid should be analyzed microbiologically,
and also cytologically if there is suspicion of a neoplastic cystic
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mass [384]. Following aspiration of the cyst fluid, a scolicidal
agent such as 96% ethanol [404] or hypertonic saline (20%)
[405] is injected into the cavity. The amount should not exceed
1/3 of the initial cyst volume. For cysts >600mL, a maximum
amount of 200mL is advised [384]. After a period of 5–20 min-
utes, the fluid is re-aspirated [384]. With the potential for ana-
phylactic reactions, patients should have IV access during the
procedure and vital parameters should be monitored [406]. The
incidence of severe anaphylaxis is 1–2% [407]. It is crucial to ex-
clude possible biliary communication of the cyst. Bilirubin in the
aspirate can immediately be evaluated with commercially avail-
able dip-sticks. Cystography may be performed by injecting con-
trast material into the cyst cavity to ascertain if the cyst has a
connection with the biliary system. It is suggested that if the as-
pirate is not clear or colorless, but contains bile, then scolicidal
agents should not be administered [268]. A counter-suggestion
indicates that hypertonic saline may be given with caution, with
no biliary damage related to PAIR being reported [396].
Outcome
RCTs showed PAIR to be superior to albendazole alone [408] and to
surgical treatment [387, 409]. A meta-analysis comparing the clin-
ical outcomes for 769 patients with hepatic CE treated with PAIR
plus albendazole or mebendazole with 952 matched historical
controls undergoing surgical treatment alone. PAIR combined
with albendazole was more effective than surgery and was asso-
ciated with a lower rate of adverse events and a shorter hospital
stay. Clinical and parasitologic cure occurred in 95.8% of patients
undergoing PAIR and in 89.8% of surgical controls and disease re-
currence occurred in 1.6% and 6.3%, respectively [407]. Retrospec-
tive studies favor PAIR over surgery in Gharbi type I and II cysts and
found surgical treatment most appropriate in the other Gharbi
types [401, 410].
A meta-analysis reported severe adverse events (anaphylaxis, cyst
infection, abscess, sepsis, biliary fistula) in 7.9% of patients treated
with PAIR plus albendazole compared to 25.1% of surgically treat-
ed patients. Minor adverse events have been observed in 13.1% of
patients treated with Pair plus albendazole versus 33% of surgical-
ly treated patients [407].
Recommendation 49
US-guided PAIR is the most appropriate treatment for Gharbi
type I and II or WHO CE1 and CE3(A) abdominal hydatid cysts
(LoE 2b, GoR B). Strong consensus (100%).
Recommendation 50
PAIR should always be accompanied by measures to manage
possible anaphylaxis (LoE 5, GoR D). Broad agreement (93%).
Recommendation 51
Albendazole should be started prior to PAIR (LoE 2b, GoR B).
Strong consensus (100%).
Post-procedure care
After the PAIR procedure, the patient should be turned onto the
side of puncture, and kept in this position for at least 30 minutes;
this may help to avoid leakage from the puncture site. The patient
should be hospitalized for one night and observed for late allergic
reactions and pain. The following day, after US examination, the
patient may be discharged [396].
Follow-up
Follow-up may be scheduled at one week, one month, three
months, six months after PAIR and then annually. CT may be nec-
essary during follow-up, to better depict multiple cysts and calci-
fication [401, 409].
Percutaneous transhepatic cholangiodrainage (PTCD)
!
Introduction
Percutaneous transhepatic cholangiography and drainage (PTCD)
is a commonly used procedure for the diagnosis and treatment of
benign and malignant biliary diseases [411, 412]. PTCD also al-
lows therapeutic interventions, such as placement of a stent
across amalignant stricture, dilatation of benign biliary strictures
and extraction of biliary tract stones [413].
Endoscopic retrograde cholangiography versus PTCD ver-
sus endoscopic ultrasound-guided cholangiodrainage
Endoscopic retrograde cholangiography (ERC) is the method of
choice for patients with indications for (therapeutic) biliary access
[414, 415]. The following surgically altered anatomical situations
have a high likelihood for ERC failure: Roux-en-Y with gastric
bypass, Kausch-Whipple resection, pylorus-preserving Whipple
resection, Roux-en-Y with hepaticojejunostomy, choledochojeju-
nostomy, and pancreaticojejunostomy [416]. Patients with a pre-
viously performed surgical Billroth I and II gastrectomy were not
a problem for conventional ERC.
Alternative methods are PTCD, endoscopic ultrasound (EUS)-guid-
ed interventions (EUS cholangiodrainage, EUS-CD) [293] and bal-
loon-assisted enteroscopy (BAE). BAE is only of use if the papilla
or the biliary-enteric anastomosis is not reached by conventional
endoscopic methods. PTCD and EUS-CD can be useful in these si-
tuations as well, if papilla cannulation or passage over a stenosis
fails. Here, either method can be used for a rendezvous maneuver
with ERC or as the definite procedure [417]. The role of PTCD is not
clearly defined in guidelines issued by other professional societies.
In malignant hilar strictures, the European Society of Gastrointes-
tinal Endoscopy (ESGE) recommends that the choice between ERC
and PTCD is based on local expertise [418] but refers to level 1 evi-
dence for fewer infectious complications with PTCD compared to
ERC. They recognize that combined expertise is not available in
many centers. PTCD access is not mentioned for patients with com-
mon bile duct (CBD) strictures. The American Society of Gastroin-
testinal Endoscopy (ASGE) guideline for ERCP in diseases of the
biliary tract and the pancreas does not mention either PTCD or
EUS-guided techniques [414]. The American Society for Gastroin-
testinal Endoscopy (ASGE) guideline for the role of endoscopy in
the evaluation and treatment of patients with biliary neoplasia
[419] refers to EUS-guided or percutaneous techniques in case of
failure of ERC without further information. The 2013 Tokyo guide-
lines on the diagnosis and treatment of cholangitis refer to PTCD as
the second choice treatment in patients with cholangitis. These
guidelines state that EUS-guided techniques are not well estab-
lished and recommend their use only if ERC or PTCD fails [415].
EUS-guided techniques are well established as a safe and effective
alternative to PTCD when ERCP fails [293].
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Special problems
PTCD: Left versus right lobe
Typically right-sided procedures are preferred, but left-sided PTCD
is feasible, both with and without US guidance [420]. A review of
conventional PTCD procedures reported a non-significant increase
in significant hemobilia of 1.5–5.2% if the left approach was cho-
sen [421].
Ultrasound guidance versus fluoroscopic guidance
A blind percutaneous puncture of peripherally located intrahepa-
tic bile ducts has limitations especially with non-dilated bile
ducts [422, 423]. Real-time imaging with US is useful for the gui-
dance of PTCD (US-PTCD), especially in patients with non-dilated
ducts and for left-sided PTCD [420, 424, 425]. Fluoroscopy deli-
vers significant irradiation both to the patient and to the inter-
ventional team. The “As Low As Reasonably Achievable” (ALARA)
principle should be applied [426].
A study comparing US-PTCD with fluoroscopy-guided PTCD
[427] shows advantages for US guidance regarding intervention
success and complications. The Society of Interventional Radiolo-
gy guidelines does not refer to the use of US guidance for PTCD
[428]. Other studies focus on feasibility, technical details or sub-
groups [420, 424, 425]. No prospective comparative studies are
available, but authors recommend US guidance during the punc-
ture procedure as an extrapolation from other interventional
procedures where US is effective, efficient and safe in comparison
to a “blind” technique, e. g. placement of central venous catheters
and nerve blocks [429, 430]. CEUS has been successfully used to
facilitate the efficacy of US-guided PTCD and for the detection of
catheter dislodgement and other complications [431–434].
Recommendation 52
For initial puncture in PTCD ultrasound guidance should be
considered (LoE 4, GoR C). Strong consensus (100%).
Level of obstruction
US can be of advantage in patients with hilar obstruction to iden-
tify and allow puncture of peripheral ducts to facilitate a suffi-
cient bile duct length for Seldinger maneuvers.
Presence of obstruction
Patients with biliary leakage and non-dilated ducts are proble-
matic if ERC fails. US allows targeting of certain areas in which
the bile duct lumenmay be seen even in the absence of duct dila-
tation [424].
Percutaneous cholecystostomy
!
Introduction
Acute calculous cholecystitis (ACC) is a common cause of acute
surgical admission. Early cholecystectomy (CCE) is a widely ac-
cepted method of treatment [435]. Laparoscopic cholecystect-
omy (LCCE) in acute cases has minimal morbidity [436]. In high-
risk patients morbidity and mortality increase to 14–46% [437].
Alternatively, percutaneous cholecystostomy (PC) is a bridging
process, especially in otherwise healthy patients (e. g. ASA I and
II) who are severely septic and may become fit in due course for
semi-elective surgery [438].
US-guided percutaneous cholecystostomy (USPC), first reported
in 1979 [439], was further developed [440] and has become es-
tablished as a minimally invasive alternative in patients not con-
sidered fit for cholecystectomy.
Clinical efficacy
A meta-analysis of 53 studies (n =1918 patients) showed no
study comparing the outcomes of PC and CCE [441]. Successful
PC was reported for 85.6 % of patients. Catheter displacement
was reported in 8.57% (98/1144 patients, 35 papers), and adverse
events of all types, most frequently pneumonia, were seen in
6.3 % (44 papers). A mortality of 15%was reported for PC, defined
as 30-day mortality or in-hospital death. The mortality rate
caused by biliary infection was 3.6 % (64/1768 patients, 47 pa-
pers). Procedure-related mortality rate of PC was 0.4% (7/1861
patients, 51 papers). The mortality after elective CCE following
USPC was 15.4 % [441]. A decrease in mortality from 22% in
1996 to 13.3% in later studies is recorded [442–446].
Most studies lack comparative data so the conclusions are subjec-
tive, preventing valid comparison of success, morbidity, mortal-
ity and adverse events [447]. A comparative study of USCP fol-
lowed by LCCE and primary LCCE in two matched groups of
high-risk patients found USCP combined with LCCE superior to
LCCE alone with regard to duration of operation, conversion rate
to open CCE, length of postoperative hospital stay, and adverse
events [448]. A retrospective study comparing outcomes of USCP
followed by LCCE compared with LCCE alone in elderly high-risk
patients with acute cholecystitis reported a significantly lower
rate of conversion to open CCE for patients treated with USCP fol-
lowed by LCCE. Perioperative mortality and postoperative mor-
bidity did not differ between the two treatment strategies [449].
Examination of outcomes of PC and CCE in patients with acute
cholecystitis (n =248229 calculous and 58518 acalculous acute
cholecystitis patients) found patients receiving PC were more
likely to be older with additional comorbidities. Patients treated
with PC had lower complication rates compared with patients
treated by CCE. However, patients who received PC had a higher
mortality and longer length of stay [450].
Patients with grade III acute CC [451] defined as having cardiovas-
cular dysfunction (hypotension requiring catecholamine therapy),
neurological dysfunction (reduction of consciousness), respiratory
dysfunction, renal dysfunction, hepatic or hematological dysfunc-
tion (platelets below 100000/µL) are thought to be candidates for
the interventional approach. In pregnant women with failure of
conservative treatment [452], USPC has been suggested particular-
ly during the 1st and 3rd trimester. Multi-disciplinary discussion
between the surgeon, the gynecologist and the interventionalist
is necessary in these patients.
With high-risk hemodialysis patients, allocating patients unfit for
surgery to USPC, USPC patients had a worse outcome than CCE pa-
tients. This may be attributed to the different risk assessment of
both groups rather than to a higher risk of USPC [453].
Poor candidates for surgery due to chronic illnesses can also be
treated conservatively, and USPC can be reserved for patients not
recovering after 3 days. This approach cannot be used in patients
with severe sepsis, who should be treated as soon as possible [454].
Evaluation of US-guided PC (USPC) for patients with acute acalcu-
lous cholecystitis (AAC) is more difficult because it is normally a
complication of serious medical and surgical illnesses [455, 456].
A study compared clinical efficacy and adverse events of PC and
CCE in a large group of severely ill patients with AAC and showed
PC to be a safe and cost-effective bridging treatment strategy,
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with perioperative outcomes superior to those of open CCE. Com-
pared with open or laparascopic CCE (n=1021), PC (n=704) was
superior in terms of morbidity, intensive-care unit admissions,
length of hospital stay, and costs [457]. Two studies showed that
in seriously ill patients with AAC, PC is an effective procedure and
a good alternative for patients unfit to undergo immediate sur-
gery because of severe sepsis or an underlying comorbidity, and
may be regarded as a definite treatment option in the majority of
patients [444, 445].
In severely ill patients with suspected AAC, USPC should not be
performed before diagnostic assessment has confirmed the diag-
nosis, with USPC being preferable to surgery in severely ill patients.
A study comparing USPC with gallbladder aspiration in patients
with acute cholecystitis showed superiority of USPC in terms of
clinical outcome, but similar complication rates [458]. A compar-
ison of both methods suggested similar clinical efficacy, but re-
ported lower complications for gallbladder aspiration [459].
Data is limitedwith respect to the duration of gallbladder drainage.
Before removal of the drain, laboratory and clinical data should
confirm resolution of sepsis [460]. Patients should be re-evaluated
following recovery to assess fitness for elective surgery. Cholecys-
titis recurrence of 10–30% is reported, and should be weighed
against the mortality and morbidity risk in the individual patient.
In severely chronically ill patients, recovery is rarely achievable
and USPC may be regarded as the definitive treatment. If cohorts
treated with both methods are compared, patients with USPC ty-
pically have a higher morbidity and mortality than CCE patients,
explained by the difference in the patient’s acute or chronic
health status. According to a meta-analysis of the available data,
elective surgery was performed in 38% (681/1787, 48 papers)
[441] and emergency surgery in 4.5% (77/1724; 47 papers).
Recommendation 53
Percutaneous ultrasound-guided gallbladder drainage may be
considered in patients with acute calculous cholecystitis as-
sessed to be unfit for surgery (LoE 3b, GoR B). Strong consen-
sus (100%).
Recommendation 54
In patients with acute acalculous cholecystitis unfit for sur-
gery, percutaneous ultrasound-guided gallbladder drainage
should be considered after diagnostic puncture (LoE 2c, GoR
B). Strong consensus (100%).
Drainage route
The transhepatic route has advantages regarding tract formation
and the avoiding of peritonitis [442, 461]. The transperitoneal ap-
proach has been reported to be no different in relation to compli-
cations, but formation of a mature tract without leakage as a pre-
condition for catheter removal is significantly delayed compared
with the transhepatic approach [461–463]. EUS-guided trans-
mural gallbladder drainage may be performed as an alternative
to USPC [293].
Recommendation 55
Ultrasound-guided percutaneous gallbladder drainage should
be performed transhepatically (LoE 2b, GoR B). Strong consen-
sus (100%).
Percutaneous gastrostomy
!
Introduction
Gastrostomy can be offered when oral food uptake is temporarily
or permanently compromised. Gastrostomy may be used in pa-
tients with neurological disorders (e. g., neurological degenera-
tion) and advanced (oncological) diseases, e. g. in gastrointestinal
stenosis with intractable vomiting where surgical treatment is
not feasible or is declined. The endoscopic approach (percuta-
neous endoscopic gastrostomy, PEG) with the “pull” technique is
the most common technique. An alternative is the introducer
technique (“push” technique). There is evidence that the introdu-
cer technique causes fewer peristomal infections [464, 465].
Image-guided percutaneous gastrostomy (without endo-
scopic access)
The percutaneous approach (image-guided percutaneous gas-
trostomy, PG) can be performed under fluoroscopy (radiological-
ly inserted gastrostomy, RIG) or US guidance (USPG). A multi-
center survey of RIG with 684 patients in 17 centers found a
mortality of 1% and a complication rate of 5% [466]. With PEG, a
prospective study (n=484) reported a high incidence of compli-
cations at 2 and 8 weeks of 39% and 27%, respectively [467]. A
retrospective study [468] compared PEG and RIG insertions and
found PEG to be superior with regard to early mortality, mainly
from pneumonia.
US guidance in experienced hands allows the identification of the
position of (a) the stomach, (b) the liver, and (c) inmost instances,
the transverse colon. Usually the stomach is filledwith water by a
nasogastric tube, but if US is used to assist endoscopy, air disten-
sion is sufficient.
US may be used in the following situations:
▶ In cases of anticipated difficulty locating the stomach (scars,
advanced gastric cancer, obesity, surgically altered stomach
anatomy).
▶ In endoscopic approach when transillumination fails.
▶ In cases without access to the upper gastrointestinal tract
(complete esophageal obstruction).
In 15 patients with failure of endoscopy, all but one eventually had
successful USPG. The reasons for the failure of PEG were scar for-
mation, unusual stomach location, obesity, tumor infiltration and
peritoneal carcinosis [469]. It is reported that US together with
fluoroscopy after filling the stomach with water via a nasogastric
tube is a feasible technique [470]. 154 patients underwent US-
guided stomach puncture using this water-filled stomach method
and T-fastener insertion was possible in all patients. The authors
then switched to fluoroscopy and placed a 14F feeding tube. Mor-
tality was 2% and major complications occurred in 3% [471]. Fol-
lowing failed endoscopy in 11 patients, a new gastropexy device
had a 100% success rate [472]. If USPG is performed, the procedure
should include gastropexy (via T-fasteners or anchors) to prevent
catheter dislodgement.
Recommendation 56
In cases in which conventional endoscopically guided gastric
puncture fails, ultrasound-assisted gastric puncture may make
it possible to accomplish percutaneous gastrostomy (LoE 4,
GoR C). Broad agreement (76%).
The use of US guidance for PEG in patients in whom the conven-
tional technique with a nasogastric tube was not possible (upper
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gastrointestinal tract obstruction) and prevented air filling of the
stomach has been reported. In 26/27 patients a stomach punc-
ture under US guidance with a 22 gauge needle was possible to
allow air insufflation [473]. Similar success was reported in 7/9
patients with the same technique [474].
Recommendation 57
When placing a nasogastric tube is not possible, the stomach
can be punctured under ultrasound guidance and distended
with air or water to facilitate percutaneous image-guided gas-
trostomy (LoE 4, GoR C). Broad agreement (86%).
Antibiotic prophylaxis is mandatory for PEG using the pull tech-
nique for prevention of peristomal infection. For introducer tech-
niques, antibiotic prophylaxis is not necessary. The database for
antibiotic prophylaxis in PEG is comprehensive [475]. There is
data for RIG showing no wound infections [466]. In general, the
introducer technique has a lower infection rate [465]. Data from
US-guided techniques are not available but may be extrapolated
from data for RIG. (●" Fig. 1)
Percutaneous nephrostomy
!
Introduction
Percutaneous nephrostomy (PCN) remains the procedure of choice
for temporary drainage of the obstructed collecting system when
the transureteral (or retrograde) approach is not indicated or fea-
sible [476, 477]. PCN is also used for urinary diversion and to gain
access to the urinary tract for subsequent interventional urologic
procedures. PCN can be successfully performed in 95–98% of pa-
tients who have a dilated renal collecting system [268].
Nephrostomy placement can potentially injure the five surround-
ing structures: the pleura, the diaphragm, the colon, the spleen
and the liver. In practice, pleural and diaphragm injuries are by
far the most common, with colon injury occasionally reported
and spleen or liver injury rarely reported. The risk of pleural
transgression or diaphragmatic injury is minimized when ne-
phrostomy placement is below the 12th rib [478]. Approximately
5% of patients lying prone have a retrorenal colon at the level of
the lower renal poles [479, 480].
Indications and contraindications
Indications
PCN may be performed for diagnostic or therapeutic purposes
[481, 482].
▶ Relief of urinary obstruction related to malignancy, urinary
stones or iatrogenic causes [482].
▶ Pyonephrosis and obstructive acute pyelonephritis.
▶ Urinary diversion in patients with urinary fistula, leakage or
hemorrhagic cystitis [478, 483].
▶ Access for endourologic procedures, such as nephrolithotomy
and removal of urinary stones, dilation or stenting of a ureteral
stricture [481].
▶ Diagnostic testing, such as antegrade pyelography, ureteral
perfusion (Whitaker test) [478].
▶ Specific situations, e. g., uroenteric diversion.
▶ Treatment of urolithiasis in transplanted kidneys and external
malignant obstruction [484–487].
Contraindications
There is no absolute contraindication for PCN, but the benefits
and risksmust beweighed for each individual [481, 482]. Relative
contraindications are:
▶ Renal vascular malformations such as an arterial aneurysm
[478],
▶ Severe life-threatening electrolyte imbalances such as hyper-
kalemia, or severe metabolic acidosis [481],
▶ Severe coagulopathy [488].
Imaging modalities
The optimal imaging methods to guide PCN vary at individual
centers. The procedure can be performed with the guidance of
fluoroscopy, US, CT, and various combinations of those tech-
niques [489–491].
Fig. 1 Ways to perform percutaneous gastrosto-
my, focusing on the use of ultrasound guidance.
*Most investigators use ultrasound for puncture
and filling of the stomach and switch to fluoroscopy
to guide the wire and dilatator and to perform tube
maneuvers.
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Fluoroscopy
Radiological methods may be necessary to determine whether
the puncture needle and PCN catheter have been successfully in-
serted into the renal pelvis and to determine the site and degree
of obstruction [492, 493].
Ultrasound guidance
US-guided puncture of the collecting system with subsequent
placement of the drainage tube under fluoroscopic control is re-
garded as the standard technique for PCN, particularly in the ab-
sence of dilatation of the urinary tract [478, 494, 495]. US is help-
ful to identify the most appropriate calyx for puncture and the
presence of stones or blood clots or other intraluminal filling de-
fects and to avoid damage to surrounding organs [496]. In addi-
tion, it is an ideal method for patient follow-up [496].
Recommendation 58
Percutaneous nephrostomy can be effectively performed under
ultrasound guidance (LoE 2b, GoR B). Strong consensus (100%).
Injection of US contrast agents via a needle or catheter can also
confirm whether the needle or PCN catheter have been correctly
inserted in the renal pelvis, with reduction in radiation exposure
which may be especially important in the first trimester of preg-
nancy [492]. Fluoroscopy is recommended to determine the posi-
tion of the needle and guidewire. The catheter can be visualized
by injecting diluted US contrast agent.
Pre-procedure preparation
Hyperkalemia and coagulopathy should be corrected prior to the
procedure [482]. Prophylactic antibiotics are widely used in pre-
paring patients for PCN [497], but are not recommended if the ur-
ine is sterile. Antibiotic cover is mandatory in pyonephrosis. Other
aspects of patient preparation are identical to those of other inter-
ventional procedures; adequate fasting is required if conscious se-
dation is planned [481].
Technical aspects and indications
Methods
Positioning
The risk of adjacent organ injury during percutaneous nephros-
tomy is minimized when the nephrostomy is inserted below
the 12th rib. Catheter placement through a calyx, rather than
through an infundibulum or directly into the renal pelvis, has
the lowest risk of vascular injury. Attempts should be made to
achieve catheter placement through a calyx, particularly if percu-
taneous nephrolithotomy or other large-bore catheter placement
is considered [478]. A 22–20 gauge needle is recommended for
ultrasound-guided PCN if the Seldinger technique is used to in-
troduce the 0.018 inch guidewire. The introducer is then inserted
and provides access to the standard 0.035 inch guidewire.
Seldinger or trocar technique
Several direct and wire-guided (Seldinger) methods of PCN tube
placement have been described. US-guided PCN tube placement
has a success rate of 92–94% [498, 499]. The trocar and Seldinger
techniques are equally effective [500].
Size
The catheter size depends on the purpose of the nephrostomy. A
6–10F catheter is recommended for PCNwhile simple urine drain-
age can be achieved with a 5–8F catheter. If the collecting system
is punctured for further procedures (e. g., tumor or stone removal)
or in procedures complicated by gross hematuria, a larger catheter
may be considered (14–22F).
The smaller tubes are less traumatic and easier to insert but do
not drain the kidney as effectively as larger tubes and are less ef-
fective in decompressing the urinary tract. Larger tubes cause
more trauma and are slightly more difficult to insert but offer
better drainage of the kidney and decompression of the urinary
tract. Malecot-type catheters require a skin suture, while balloon
catheters do not. Catheters that are indwelling in the renal pelvis
are more secure than nephro-stent–type tubes [501].
Recommendation 59
In percutaneous nephrostomy, access via the posterior-infer-
ior calyces should be attempted to reduce the risk of pleural
and vascular injury (LoE 5, GoR D). Strong consensus (100%).
Post-procedure catheter management and patient care
Vital signs should bemonitored during initial recovery (> 24 hours)
[481]. Urinary output should be charted. Urine will be blood-ting-
ed initially but prolonged hematuria (> 24–48 hours) should serve
as an alert to persistent bleeding from vascular injury [481, 502]. If
bleeding occurs, the catheter should be clamped off to tamponade
the collecting system. If there is a low risk of infection, antibiotics
may be discontinued. However, intravenous antibiotic therapy
continues for patients with pyonephrosis, fever and chills. The
catheter should be routinely flushed with normal saline and aspi-
rated to reduce blockage [268]. Long-term indwelling catheters
should be changed every 4–6 weeks [268].
Complications
Major complications can be classified into three types: Severe
bleeding (hemorrhage) [482, 502–504], injury to adjacent struc-
tures (such as pleural involvement, colonic perforation) [482,
502, 505] and severe infection/sepsis [481, 506, 507]. The inci-
dence of major complications ranges from 0–8% [476, 491, 508,
509]. Minor complications occur in 2–38% [476, 491, 508, 509].
Transient gross hematuria is usually present. Other minor compli-
cations that may be seen include urine leakage, pain, fever and
catheter-related complications (obstruction or dislodgement).
Suprapubic puncture of the bladder
!
Introduction
Suprapubic puncture of the bladder is a safe and reliable method
to drain the bladder, while avoiding urethral catheterization
[510]. US guidance improves the success rate [511–514]. A study
reported a success rate of 95.8 % for catheter insertions using US
guidance in 24 patients where insertion of a suprapubic catheter
without image guidance had failed [515], and the British Associa-
tion of Urological Surgeons (BAUS) guidelines have recommen-
ded US guidance whenever possible [516].
US is recommended to assess the position and volume of the
bladder, and to avoid the inadvertent puncture of other struc-
tures [517, 518].
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Recommendation 60
Puncture and drainage of the urinary bladder should be per-
formed under ultrasound guidance (LoE 1b, GoR B). Strong con-
sensus (100%).
Main indications
Suprapubic puncture of the bladder is indicated in pathological
conditions of the bladder, prostate or urethra that require tem-
porary or permanent drainage of the bladder when urethral ca-
theterization is not possible or is contraindicated.
Contraindications to percutaneous US-guided procedure
▶ Absence of visualization of the bladder on US.
▶ Uncorrected coagulopathy.
▶ Other relative contraindications are those secondary to com-
plex anatomy due to congenital disorders, habitus, previous
surgery or infiltrative pelvic cancer.
Suprapubic puncture can be performed using CT guidance if the
bladder is seen on US and if the bladder contains large amounts
of air (e. g. in patients with an indwelling urethral catheter) as
well as in cases of pelvic trauma, congenital disorders or previous
complicated surgery [514].
Materials and technical problems
The procedure is performed under sterile conditions after the ad-
ministration of local anesthesia. Sedation may be useful in selec-
ted cases. The bladder is filled by transurethral catheter or, when
urethral catheterization is not possible, a US-guided suprapubic
approach is used to instill saline. The position and volume of the
bladder are identified by US and US is helpful for real-time gui-
dance of the percutaneous puncture [517, 518]. Both needle-
guide and free-hand techniques may be used, and fluoroscopy
or US contrast agent administration can guide final placement of
the catheter after voiding. Different suprapubic techniques have
been described. Catheters are placed by either the Seldinger (the
safest way) or the trocar technique, with dilation of the percuta-
neous track when necessary. At the end of the procedure, the
catheter must be fixed to the abdominal wall. Catheters of 10F
are large enough to relieve acute urinary retention. Large cathe-
ters (> 16F) are recommended in patients who require prolonged
drainage of the bladder in circumstances such as bladder rupture
or complicated urethral stricture [510]. Smaller catheter (5–7F)
can be used for suprapubic cystography in order to fill the blad-
der with diluted iodinated contrast agents.
Complications
US guidance can decrease the complication rate of suprapubic
puncture [510, 514, 519]. Major complications are rare and in-
clude perforation of intestinal loops [520]. Minor complications
include pain, infection, hemorrhage, blockage, hematuria and
catheter misplacement, all of which are less common when US
guidance is performed [514, 519, 521].
Palliative care
!
Palliative care patients often have alterations in locoregional anat-
omy, vascular patterns and coagulation factors. Therefore, for any
invasive procedure it is recommended to consider US guidance to
improve safety and help minimize complications and patient dis-
comfort. There are no contraindications of US-guided procedures
in palliative care [522]. The management of cancer complications
indicates potential roles for home-performed US and US-guided
procedures at the end of life [523].
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